👪

Inheritance

1

Autosomal dominant HP:0000006

Heterozygous MIR96 substitutions segregate with progressive hearing loss in the founding Spanish and Italian families. Each child has a 50% chance of inheriting the causal allele; age-specific penetrance and severity remain uncertain. Normal hearing in heterozygous mouse deletion models informs mechanism but does not establish that dosage effects are irrelevant to every human allele.

Autosomal dominant inheritance

Show evidence (3 references)

PMID:19363479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss"

The inheritance mode as established in the two founding families.

PMID:22038834 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We screened 882 NSHL patients and 836 normal-hearing Italian controls and identified one putative novel mutation within the miR-96 gene in a family with autosomal dominant NSHL."

An independent dominant pedigree, and the screening denominator behind it.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic variant to each child."

General Mendelian transmission counseling; penetrance and onset remain separate questions.

◈

Mechanistic Hypotheses

1

mir96_allele_specific_cochlear_dysfunction

Altered miRNA targeting perturbs hair-cell maturation and maintenance, bundle function, synaptic function and survival. These routes are supported primarily in mice and vary by allele, zygosity and developmental stage. Their relative contributions in human carriers remain provisional.

Pathograph links

Loss of Repression of Normal miR-96 Targets -> Dysregulation of the Hair Cell Maturation Gene Programme INDIRECT UNKNOWN INTERMEDIATES

Repression of Novel Targets Acquired by the Mutant Seed -> Dysregulation of the Hair Cell Maturation Gene Programme INDIRECT UNKNOWN INTERMEDIATES

Dysregulation of the Hair Cell Maturation Gene Programme -> Impaired Hair Cell Maturation INDIRECT UNKNOWN INTERMEDIATES

Dysregulation of the Hair Cell Maturation Gene Programme -> Loss of Cochlear Amplification INDIRECT UNKNOWN INTERMEDIATES

Dysregulation of the Hair Cell Maturation Gene Programme -> Impaired Adult Hair Cell Maintenance INDIRECT UNKNOWN INTERMEDIATES Adult deletion experiments support continued regulatory requirements, but the relevant targets in human seed-variant carriers are unresolved.

Impaired Hair Cell Maturation -> Stereociliary Bundle Dysfunction INDIRECT UNKNOWN INTERMEDIATES

Impaired Hair Cell Maturation -> Inner Hair Cell Synaptic Dysfunction INDIRECT UNKNOWN INTERMEDIATES

Stereociliary Bundle Dysfunction -> Outer Hair Cell Degeneration INDIRECT UNKNOWN INTERMEDIATES

Stereociliary Bundle Dysfunction -> Loss of Cochlear Amplification INDIRECT UNKNOWN INTERMEDIATES

Impaired Adult Hair Cell Maintenance -> Loss of Cochlear Amplification INDIRECT UNKNOWN INTERMEDIATES Proposed contribution of impaired adult hair-cell function; the inducible study did not isolate every component of the hearing deficit.

Inner Hair Cell Synaptic Dysfunction -> Progressive Sensorineural Hearing Loss INDIRECT UNKNOWN INTERMEDIATES

Outer Hair Cell Degeneration -> Loss of Cochlear Amplification INDIRECT UNKNOWN INTERMEDIATES

Loss of Cochlear Amplification -> Progressive Sensorineural Hearing Loss INDIRECT UNKNOWN INTERMEDIATES

?

Discussions and Knowledge Gaps

3

Does altered CLIC5 regulation contribute to human seed-variant DFNA50, and does its direction match the loss-of-function models?

KNOWLEDGE GAP OPEN mir96_clic5_direction

Attached to

pathophysiology#Loss of Repression of Normal miR-96 Targets

HEI-OC1 mimic/reporter assays support direct miR-96/miR-182 repression of CLIC5. Whole-cluster knockout raises Clic5 in P1 cochlea, and the 2025 single-Mir96-knockout study reports Clic5 among upregulated genes in P28 whole cochlea. Neither observation establishes a causal CLIC5 pathway in human seed-variant disease. The expected effect of losing normal repression is increased CLIC5, distinct from biallelic CLIC5 loss in DFNB103, but acquired targets and tissue composition can alter the net result. GSE255796 provides sorted mixed cochlear/vestibular hair-cell data for further analysis; its main text does not give a Clic5-specific result. No new gene-level analysis was performed in this review.

Show evidence (4 references)

PMID:22889583 SUPPORT DIRECT PRIMARY RESULT In Vitro

"miR-96 and miR-182 were found to be specifically overexpressed in HEI-OC1 cells into which mimics of these molecules had been transfected by liposomes causing the downregulation of CLIC5 at both the mRNA and protein levels"

Direct cell-line evidence establishes repression; it does not determine CLIC5 abundance in human mutant hair cells.

PMID:30575790 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Several predicted target genes of the miR-183/96/182 cluster that are known to play important roles in HC development and function, including Clic5, Rdx, Ezr, Rac1, Myo1c, Pvrl3 and Sox2, are upregulated in the cochlea."

The same direction confirmed in vivo, in a cluster-null cochlea.

PMID:38826689 NO_EVIDENCE DIRECT PRIMARY RESULT Model Organism

"This Mir96Dmdo HC-specific RNA-seq data set is currently the only data set available for evaluating the regulatory cascade of Mir96Dmdo specifically in HCs."

Identifies the dataset that could settle the question. Graded NO_EVIDENCE because the paper states the resource exists without reporting CLIC5 in it - it neither supports nor refutes the claim.

+ 1 more reference

Why does a mouse carrying the human MIR96 +13G>A allele in heterozygosis hear normally for a year, when the same heterozygous allele causes progressive hearing loss in the Spanish family it was taken from?

HUMAN MODEL MISMATCH OPEN mir96_13ga_human_model_mismatch

Attached to

pathophysiology#Progressive Sensorineural Hearing Loss

The human +14C>A and +13G>A alleles produce distinct mouse phenotypes and transcriptomes. +13G>A heterozygotes retained normal thresholds through one year, while the corresponding human allele segregated with progressive hearing loss. The authors proposed species-specific acquired targets, including predicted +13G>A sites in human RAB11A that are absent from mouse Rab11a. This candidate has not been validated as the cause of the mismatch. Neither identical seed sequence nor a human-matched substitution guarantees conserved target repertoires. The discrepancy constrains transfer of mechanism and therapy between alleles.

Show evidence (2 references)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"While the Mir96+14C>A heterozygotes mimic the phenotype observed in the family with the equivalent mutation, the Mir96+13G>A heterozygotes escape deafness while the same mutation causes progressive hearing loss in humans"

The mismatch stated by the authors of the models.

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"the heterozygous phenotypes differ markedly, with only one mutation resulting in hearing impairment in heterozygosis"

The divergence between the two human-allele lines, summarised.

Can allele-specific editing or transcriptome-guided drugs provide durable clinical benefit in DFNA50?

KNOWLEDGE GAP OPEN dfna50_preclinical_translation

Attached to

treatments#Experimental AAV2 Mutant-Allele Editing treatments#Experimental Amitriptyline

The studies establish mouse proof of concept, not human efficacy. Editing benefit depends on the treatment window and surviving cells; safety is bounded by the assays and doses used. The amitriptyline effect was temporary at high experimental exposure. The multiplex guide construct targeted +13G>A, +14C>A and the mouse-derived +15A>T sequence in engineered cells; it did not demonstrate rescue of all human MIR96 alleles and did not include the Italian +57T>C allele. General hearing and communication care remains appropriate while these approaches are investigated.

Show evidence (2 references)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"This is a proof of concept rather than a suggestion that amitriptyline be used as a treatment for humans carrying the MIR96+14C>A mutation, for several reasons."

Explicitly limits the result to preclinical proof of concept.

PMID:38985856 SUPPORT DIRECT PRIMARY RESULT Model Organism

"For the applications in humans, the system has to be further evaluated, including the testing in nonhuman primates and human inner ear specimen."

The editing authors identify the translational work still needed.

⚙

Pathophysiology

12

MIR96 Seed-Region Point Mutation

Mechanism confidence: Established

Heterozygous germline substitutions historically designated +13G>A and +14C>A segregated with hearing loss in two Spanish families. They affect the seed of mature miR-96-5p, altering target recognition; transfected HeLa cells also showed reduced mature miRNA accumulation. The mouse diminuendo +15A>T seed allele is distinct from these human variants.

MIR96 hgnc:31648

Genetic context MIR96 hgnc:31648 Variant type: single nucleotide variant Genomic context: noncoding exon allele_type: single-nucleotide substitution within the seed region of the mature miR-96 strand variant_origin: GERMLINE zygosity: HETEROZYGOUS

Carriers are heterozygous. The two reported human seed alleles are +13G>A and +14C>A in the historical precursor-relative numbering used by the founding papers.

Historical precursor-relative allele notation is retained. Altered target specificity and reduced miRNA abundance are separate consequences; a single loss-of-function category would not capture both.

Downstream

Loss of Repression of Normal miR-96 Targets

Repression of Novel Targets Acquired by the Mutant Seed

Show evidence (2 references)

PMID:19363479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss"

The initiating lesion is supported by the founding human pedigrees.

PMID:19363479 SUPPORT DIRECT PRIMARY RESULT In Vitro

"The identified mutations have a strong impact on miR-96 biogenesis and result in a significant reduction of mRNA targeting."

Biogenesis and target-repression assays of human alleles, rather than measurements in patient cochlear tissue.

MIR96 Precursor Processing Defect

Mechanism confidence: Provisional

The Italian +57T>C substitution lies in the precursor hairpin and the companion miR-96* (miR-96-3p) seed, while preserving the mature miR-96-5p sequence. In HeLa cells, mature miR-96 and miR-96* fell by approximately 85% and 77%, respectively, without reduced precursor abundance. A compensatory +23A>G change restored pairing, mature levels and MYRIP reporter repression. These results support defective processing, with impaired Dicer cleavage proposed rather than directly assayed. Altered targeting by the changed companion seed remains possible; it was not established by the tested reporters.

MIR96 hgnc:31648

Genetic context MIR96 hgnc:31648 Variant type: single nucleotide variant Genomic context: noncoding exon allele_type: single-nucleotide substitution in the pre-miR-96 hairpin, within the miR-96* strand variant_origin: GERMLINE zygosity: HETEROZYGOUS

Historical +57T>C allele changes precursor pairing and the miR-96-3p seed, while the miR-96-5p sequence is unchanged.

miRNA processing GO:0035196 ↓ DECREASED

Downstream

Loss of Repression of Normal miR-96 Targets

Show evidence (6 references)

PMID:22038834 SUPPORT DIRECT PRIMARY RESULT Computational

"Although located outside the mature miR-96 sequence, the detected variant replaces a highly conserved nucleotide within the companion miR-96*, and is predicted to reduce the stability of the pre-miRNA hairpin."

The location of the variant and the structural prediction. Graded COMPUTATIONAL because the destabilisation claim in this sentence is a secondary-structure prediction; the functional confirmation is quoted separately below.

PMID:22038834 SUPPORT DIRECT PRIMARY RESULT In Vitro

"We found that both miR-96 and miR-96* levels were significantly reduced in the mutant, whereas the precursor levels were unaffected."

Reduced mature products despite preserved precursor abundance support impaired processing rather than reduced precursor production.

PMID:22038834 SUPPORT DIRECT PRIMARY RESULT In Vitro

"demonstrating that the mutation hinders precursor processing, probably interfering with Dicer cleavage"

The study concludes that processing is impaired; Dicer cleavage is proposed rather than directly measured.

+ 3 more references

Loss of Repression of Normal miR-96 Targets

Mechanism confidence: Provisional

Loss of normal miR-96-mediated repression raises expression of some wild-type targets. Wild-type seed matches are enriched among upregulated transcripts in diminuendo and both human-seed knock-in mouse transcriptomes. Human-allele reporter assays support impaired repression, but expression and target repertoires in human cochlear hair cells have not been directly measured in these studies.

None

miRNA-mediated post-transcriptional gene silencing of the wild-type miR-96 target set GO:0035195 ↓ DECREASED

Downstream

Dysregulation of the Hair Cell Maturation Gene Programme

Show evidence (6 references)

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Hypergeometric P-value analysis showed that hundreds of genes were upregulated in mutants."

The scale of de-repression in the diminuendo organ of Corti: hundreds of genes rise, which is what loss of normal targeting predicts.

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"This indicates that miR-96 normally modulates expression of a broad range of target genes, and that it affects mRNA levels rather than affecting translation alone."

The Sylamer conclusion: the upregulated set carries wild-type miR-96 seed matches, so the effect is on this specific target set rather than a general one, and it is measurable as transcript abundance.

PMID:19363479 SUPPORT DIRECT PRIMARY RESULT In Vitro

"The identified mutations have a strong impact on miR-96 biogenesis and result in a significant reduction of mRNA targeting."

Biogenesis and target-repression assays of human alleles, rather than measurements in patient cochlear tissue.

+ 3 more references

Repression of Novel Targets Acquired by the Mutant Seed

Mechanism confidence: Provisional

A changed miR-96-5p seed can acquire a different target repertoire. Mutant-seed matches are enriched among downregulated transcripts in diminuendo and both human-seed knock-in lines. Normal hearing thresholds in heterozygous deletion models support a contribution from mutant RNA beyond reduced normal dosage, but do not exclude quantitative effects for every human allele. The acquired targets depend on allele and species.

None

miRNA-mediated post-transcriptional gene silencing of transcripts complementary to the mutant seed GO:0035195

Animal models

diminuendo (Mir96 Dmdo) ENU seed-mutant mouse Mouse partially recapitulates Diminuendo transcriptomes support an acquired-target signature alongside derepression of normal targets; the exact acquired repertoire is allele-specific.

Mir183/96 double-knockout mouse Mouse fails to recapitulate The deleted allele cannot produce a mutant seed RNA. Normal heterozygous hearing argues against simple dosage insufficiency in this model but does not resolve the mechanism of every human precursor allele.

Downstream

Dysregulation of the Hair Cell Maturation Gene Programme

Show evidence (6 references)

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Different genes, with target sites complementary to the mutant seed, were downregulated."

The direct transcriptomic signature of novel targeting: genes bearing the mutant seed match are the ones that go down, and they are a different set from the genes that carry wild-type sites.

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"indicating that mutant miR-96 influences expression of newly-acquired target genes"

The authors' reading of that enrichment, stated as acquisition of new targets.

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"the phenotype results from a lack of repression of normal targets even though we show a gain of repression of novel targets"

The founding mouse paper's own weighting of the two halves, which at that time put the abandoned targets first. Recorded because the weighting later shifted, and both readings should be visible.

+ 3 more references

Dysregulation of the Hair Cell Maturation Gene Programme

Mechanism confidence: Provisional

Altered miRNA targeting changes a broad hair-cell gene program. In the original P4 diminuendo organ-of-Corti experiment, Slc26a5, Ocm, Gfi1, Ptprq and Pitpnm1 were strongly downregulated. Only Ocm and prestin staining was compared with nine other deaf mutants. The original prediction analysis did not identify miR-96 sites in these five genes, but later work identified a potential diminuendo-specific site in Ptprq. Their regulation therefore cannot all be assigned to one proven indirect route. P1 sorted hair-cell RNA-seq and human-seed knock-in transcriptomes support widespread, allele-dependent changes.

None

cochlear inner hair cell CL:0000589 cochlear outer hair cell CL:0000601

SLC26A5 hgnc:9359 OCM hgnc:8105 GFI1 hgnc:4237 PTPRQ hgnc:9679 PITPNM1 hgnc:9003

organ of Corti UBERON:0002227

Downstream

Impaired Hair Cell Maturation

Loss of Cochlear Amplification

Impaired Adult Hair Cell Maintenance Adult deletion experiments support continued regulatory requirements, but the relevant targets in human seed-variant carriers are unresolved.

Show evidence (5 references)

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Microarray analysis revealed 96 transcripts with significantly altered expression in homozygotes; notably, Slc26a5, Ocm, Gfi1, Ptprq and Pitpnm1 were downregulated."

The named downregulated maturation genes and the size of the transcriptional shift.

PMID:24446963 SUPPORT DIRECT PRIMARY RESULT Model Organism

"The reduction in Ptprq observed in diminuendo mice appears to be a major contributor to the morphological, transcriptional and electrophysiological phenotype, but does not account for the complete diminuendo phenotype."

The comparison supports a partial Ptprq contribution, without a quantitative mediation estimate or a rescue experiment proving the entire causal route.

url:https://www.ebi.ac.uk/europepmc/webservices/rest/PMC7903918/fullTextXML SUPPORT INDIRECT PRIMARY RESULT Model Organism

"we found 19 genes that were significantly downregulated in the mutant and that bore matches to the mutant seed region in their 3′UTR ... The list includes one known deafness gene, ... Ptprq"

Hearing impairment due to Mir183/96/182 mutations suggests both loss and gain of function effects. (PMID:33318051; full-text XML; the cache extractor supplies a generic abstract heading as its title.) The full text includes Ptprq among predicted acquired targets, revising the original no-site interpretation.

+ 2 more references

Impaired Hair Cell Maturation

Mechanism confidence: Provisional

Complete functional maturation arrest around birth was demonstrated in homozygous diminuendo mice, with less severe or intermediate abnormalities in heterozygotes. These cells retain immature conductances and synaptic properties. This experiment does not directly establish neonatal maturation arrest in human heterozygous carriers.

None

cochlear inner hair cell CL:0000589 cochlear outer hair cell CL:0000601

inner ear receptor cell differentiation GO:0060113 ↓ DECREASED

Animal models

diminuendo (Mir96 Dmdo) ENU seed-mutant mouse Mouse partially recapitulates Single-cell physiology establishes neonatal maturation arrest in homozygotes, with an intermediate heterozygous phenotype. This is one component of miR-96 biology rather than proof of an exclusively developmental human disorder.

Downstream

Stereociliary Bundle Dysfunction

Inner Hair Cell Synaptic Dysfunction

Show evidence (1 reference)

PMID:21245307 SUPPORT DIRECT PRIMARY RESULT Model Organism

"We found that the physiological development of mutant sensory hair cells is arrested at around the day of birth, before their biophysical differentiation into inner and outer hair cells."

The timing and nature of the arrest, from single hair cell electrophysiology.

Stereociliary Bundle Dysfunction

Mechanism confidence: Provisional

Diminuendo mice show immature or disorganized stereociliary bundles, with stronger defects in homozygotes. In +14C>A heterozygous mice some outer hair-cell bundles are rounded; +13G>A heterozygotes lose some shortest-row stereocilia despite normal ABR thresholds. Direct recordings in diminuendo OHCs show reduced mechanotransduction currents and impaired adaptation, while residual currents indicate that transduction is not wholly absent as in the cluster knockout.

None

cochlear inner hair cell CL:0000589 cochlear outer hair cell CL:0000601

auditory receptor cell stereocilium organization GO:0060088 ⚠ ABNORMAL

Animal models

Mir96 +14C>A human-allele knock-in mouse Mouse partially recapitulates Some heterozygous OHC bundles adopt a U shape. The human variant is matched, but human stereociliary anatomy was not measured, so anatomical fidelity remains uncertain.

Downstream

Outer Hair Cell Degeneration

Loss of Cochlear Amplification

Show evidence (4 references)

PMID:21245307 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Moreover, maturation of the hair cell stereocilia bundle and remodelling of auditory nerve connections within the cochlea fail to occur in miR-96 mutants."

The two maturation events that fail, stated together.

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Remaining outer hair cell stereocilia bundles formed a loose U-shape rather than the precise V-shape of controls"

Heterozygous diminuendo mice have an abnormal bundle shape; their allele differs from the human variants.

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"In Mir96+14C>A heterozygotes, which have mild hearing loss by P28, some OHC stereocilia bundles have a U-shape, instead of the typical V-shape observed in wildtypes"

The same lesion reproduced by a knock-in of an actual human DFNA50 allele rather than the ENU allele.

+ 1 more reference

Impaired Adult Hair Cell Maintenance

Mechanism confidence: Provisional

Adult inducible biallelic Mir96 deletion impairs hearing before detectable hair-cell or spiral-ganglion loss. Hair-cell-specific constitutive deletion reproduces auditory impairment, whereas the tested SGN-specific deletion does not. These loss-of-function experiments support a continuing requirement for miR-96, distinct from neonatal maturation; how this requirement contributes to dominant human alleles remains uncertain.

None

cochlear inner hair cell CL:0000589 cochlear outer hair cell CL:0000601

Animal models

Constitutive and Adult-Inducible Mir96 Knockout Mice Mouse perturbs Adult deletion tests the maintenance requirement separately from congenital maturation effects.

Downstream

Loss of Cochlear Amplification Proposed contribution of impaired adult hair-cell function; the inducible study did not isolate every component of the hearing deficit.

Show evidence (1 reference)

PMID:40641557 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Hearing loss in the inducible miR-96 knockout mice is likely due to impaired HC function, as HC and SGN numbers were unchanged"

Adult induced deletion separates loss of function from earlier developmental arrest and cell loss.

Inner Hair Cell Synaptic Dysfunction

Mechanism confidence: Provisional

Diminuendo homozygotes retain immature calcium-dependent exocytosis, spherical ribbons and disorganized afferent/efferent connections. The +13G>A homozygous knock-in has fewer colocalized pre- and postsynaptic puncta at four weeks; +14C>A homozygotes did not show the same significant reduction. Synaptic pathology is allele-dependent and has not been demonstrated in human heterozygotes.

None

cochlear inner hair cell CL:0000589

Animal models

Mir96 +13G>A human-allele knock-in mouse Mouse partially recapitulates Homozygotes have fewer colocalized IHC synaptic puncta at four weeks; this measured synaptic phenotype differs from the +14C>A comparison.

Downstream

Progressive Sensorineural Hearing Loss

Show evidence (2 references)

PMID:21245307 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Moreover, maturation of the hair cell stereocilia bundle and remodelling of auditory nerve connections within the cochlea fail to occur in miR-96 mutants."

Auditory nerve connections fail to remodel in diminuendo mutants. The full text adds that the wiring defect might arise in hair cells and/or the peripheral sensory neurons, so the experiment does not uniquely assign it to one cellular compartment.

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"no significant differences were found in the number of synapses in Mir96+14C>A wildtypes, heterozygotes and homozygotes"

Preserves the negative comparison rather than universalizing the +13G>A synaptic lesion.

Outer Hair Cell Degeneration

Mechanism confidence: Provisional

Hair-cell loss contributes to later disease in mouse models even though severe dysfunction can precede it. In heterozygous diminuendo mice, outer hair cells in middle and basal regions degenerate while many inner hair cells remain. The +14C>A model also develops progressive OHC loss, and mutant-allele editing improves survival. These findings support a degenerative component without establishing a uniform human histopathology.

None

cochlear outer hair cell CL:0000601

organ of Corti UBERON:0002227

Downstream

Loss of Cochlear Amplification

Show evidence (3 references)

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"In heterozygotes many outer hair cells had degenerated in the middle and basal turns but most inner hair cells remained intact"

The cell type and cochlear location of the degeneration in heterozygotes.

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"this and previous studies suggest that the degeneration is instead a correlate or consequence of a prior dysfunction of the hair cells"

The authors' explicit ordering of dysfunction before degeneration, which is what places this node downstream of the maturation nodes rather than upstream of them.

PMID:38985856 SUPPORT DIRECT PRIMARY RESULT Model Organism

"improved OHC survival was seen across all frequency regions compared with the uninjected Mir9614C>A/+ mice"

Intervention in the human-allele model supports preservation of surviving outer hair cells.

Loss of Cochlear Amplification

Mechanism confidence: Provisional

Reduced expression of prestin and loss or dysfunction of outer hair cells provide plausible routes to impaired active cochlear amplification. Elevated DPOAE thresholds in the +14C>A model support OHC dysfunction. The normal endocochlear potential measured in diminuendo mice argues against a primary strial-potential defect in that experiment; it does not exclude every ionic or strial contribution in human disease.

None

cochlear outer hair cell CL:0000601

Downstream

Progressive Sensorineural Hearing Loss

Show evidence (3 references)

PMID:19363478 SUPPORT INDIRECT BACKGROUND Other

"Prestin is a voltage-sensitive motor molecule that mediates outer hair cell length changes responsible for amplification of sound within the cochlea"

Background physiology explains why reduced prestin could impair amplification; it is not a direct amplification measurement in this study.

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Endocochlear potentials were within the normal range"

Normal endocochlear potential in the tested diminuendo mice bounds the strial-potential explanation in that model.

PMID:38985856 SUPPORT DIRECT PRIMARY RESULT Model Organism

"a 19-dB elevation in DPOAE"

At four weeks, heterozygous +14C>A mice had elevated 32-kHz DPOAE thresholds, supporting OHC dysfunction.

Progressive Sensorineural Hearing Loss

Mechanism confidence: Established

The human endpoint is progressive bilateral sensorineural hearing loss with variable onset and severity. Mouse threshold abnormalities provide experimental support for a hair-cell mechanism but vary markedly by allele and zygosity. The +13G>A heterozygous model does not reproduce the hearing-threshold phenotype of the corresponding human family.

Animal models

Mir96 +14C>A human-allele knock-in mouse Mouse recapitulates Heterozygotes lose hearing progressively from four weeks, starting at high frequencies and spreading, which is the same shape of course as the human disease.

Mir96 +14C>A human-allele knock-in mouse Mouse rescues Two independent preclinical rescue arms have been run in this line. AAV delivery of SaCas9-KKH with a guide RNA against the mutant allele into the cochleae of presymptomatic and symptomatic adult mice improved hearing long term, with better results from earlier injection. Separately, amitriptyline - selected by matching the mutant transcriptome against anti-correlated drug expression profiles - delayed progression at high frequencies.

Mir96 +13G>A human-allele knock-in mouse Mouse fails to recapitulate Heterozygotes fail to reproduce the human hearing-threshold phenotype: ABR thresholds remain normal to one year on the tested inbred background and to six months on the mixed background. The tested noise exposure did not uncover a genotype-dependent threshold difference; subtle bundle abnormalities nevertheless occur.

Downstream

Progressive Sensorineural Hearing Impairment

High-Frequency Hearing Impairment Observed audiometric configuration in the reported families.

Show evidence (2 references)

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"in heterozygotes thresholds were raised by around 60dB"

The magnitude of the functional deficit in the heterozygous mouse.

PMID:19363479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss"

The human endpoint the mouse deficit corresponds to.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

3

Progressive Sensorineural Hearing Impairment Auditory HP:0000408

Laterality: BILATERAL

Three normal-hearing children in the Italian family carried the variant and were below the family mean onset age. The report could not distinguish age-dependent expression from incomplete penetrance; an obligate frequency across carriers is not established.

Show evidence (5 references)

PMID:19363479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss"

Progression stated in the founding description of the two Spanish families.

PMID:22038834 SUPPORT INDIRECT BACKGROUND Human Clinical

"Recently, point mutations within the seed region of miR-96 were reported in two Spanish families with autosomal dominant non-syndromic sensorineural hearing loss (NSHL) and in a mouse model of NSHL."

The Italian paper recalls the earlier Spanish report; its own proband description below provides direct clinical evidence.

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/ SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The proband shows non-syndromic, bilateral, sensorineural deafness that onset as a mild hearing impairment at"

Direct clinical description supports bilaterality and mild initial presentation in the Italian proband.

+ 2 more references

High-Frequency Hearing Impairment Auditory HP:0005101

Show evidence (2 references)

url:https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_01d1a7f4-8421-4be3-8fe7-2c2025f03ac9-2023-09-26T160000.000Z SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Autosomal dominant, progressive, high-frequency hearing loss."

ClinGen summarizes the clinical configuration in the +14C>A family.

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/ SUPPORT DIRECT PRIMARY RESULT Human Clinical

"She presents a down-sloping audiometric profile in which all frequencies are affected"

The Italian proband had broader frequency involvement.

Episodic Vertigo Vestibular HP:0002321

Show evidence (1 reference)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/ SUPPORT DIRECT PRIMARY RESULT Human Clinical

"episodes of vertigo were reported in the proband (III-2), her mother (II-2) and her brother (III-3)"

Direct human observation supports adding the previously omitted phenotype.

🧬

Genetic Associations

1

MIR96

Gene: MIR96 hgnc:31648 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (4 references)

PMID:19363479 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss"

The initiating lesion is supported by the founding human pedigrees.

PMID:22038834 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"In conclusion, we provide further evidence of the involvement of miR-96 mutations in human deafness and demonstrate that a quantitative defect of this miRNA may contribute to NSHL."

Independent replication of the gene-disease relationship in a third family.

PMID:38985856 SUPPORT DIRECT PRIMARY RESULT Computational

"Because mouse and human MIR96 sequences share 100% homology"

Sequence conservation supports guide design, but does not by itself establish conservation of downstream targets or human efficacy.

+ 1 more reference

🗃️

External Assertions

2

OMIM deafness, autosomal dominant 50 record

OMIM disease record OMIM:613074

The OMIM phenotype record for DFNA50, and the identifier the clinical literature uses for the disorder. Recorded here rather than under mappings because the DiseaseMappings class carries only ICD-10-CM, ICD-11, MONDO and NCIT slots.

ClinGen MIR96 dominant hearing-loss validity

ClinGen gene disease validity CGGV:assertion_01d1a7f4-8421-4be3-8fe7-2c2025f03ac9-2023-09-26T160000.000Z

Moderate gene-disease validity for autosomal dominant nonsyndromic genetic hearing loss, September 2023. The detailed table separates three included human alleles from unscored candidates with possible alternative genetic explanations.

💊

Medical Actions

6

Hearing Aids and Communication Support

Platform: Device

Offer hearing aids tailored to audiometric needs and communication support aligned with individual preferences, including sign language where desired. This is general genetic hearing-loss care; DFNA50-specific outcome estimates were not established in the reviewed family reports.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Habilitation for hearing loss includes improved access to sound through hearing aids or cochlear implants and, when desired, exposure to and teaching of American Sign Language."

General management guidance, not an allele-specific treatment trial.

Cochlear Implantation

Action: Surgical Procedure NCIT:C15329

Platform: Surgery

Consider cochlear implant assessment when hearing and aided speech understanding warrant it. Selection and counseling are individualized; the reviewed sources do not establish a DFNA50-specific implant prognosis.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Habilitation for hearing loss includes improved access to sound through hearing aids or cochlear implants and, when desired, exposure to and teaching of American Sign Language."

Supports cochlear implantation as a general hearing-loss management option.

Genetic Counselling and Audiologic Surveillance

Action: Genetic Counseling NCIT:C15240

Platform: Other

Explain the 50% chance of transmitting a causal heterozygous allele, variable onset/severity and uncertain age-specific penetrance. Offer appropriate family testing and serial audiologic evaluation, including in initially normal-hearing carriers.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic variant to each child."

Transmission probability is not a penetrance estimate.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Regular follow up is recommended for all individuals with genetic hearing loss"

General surveillance guidance, tailored to the individual course.

Hearing Conservation

Platform: Behavioral / lifestyle

Avoid repeated excessive noise exposure as part of general hearing conservation. The reviewed studies do not establish heightened noise vulnerability for every MIR96 allele or a disease-specific safe exposure threshold.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"persons with documented hearing loss should be counseled appropriately and repeated overexposure to loud noises should be avoided."

General hearing-conservation advice, without evidence of an allele-specific noise threshold.

Experimental AAV2 Mutant-Allele Editing

Action: Gene Therapy NCIT:C15238

Platform: Gene editing Delivery: Viral vector

Delivery target: cochlear inner hair cell CL:0000589 cochlear outer hair cell CL:0000601

Local cochlear AAV2 delivery of SaCas9-KKH and sgRNA-4.

AAV2 delivered SaCas9-KKH and an allele-specific sgRNA through the round window with canal fenestration, disrupting the mutant allele by end joining. Treatment at three or six weeks preserved hearing and hair cells; intervention at sixteen weeks did not improve thresholds. This is not correction of the nucleotide or an established human treatment. Editing and safety were assessed in selected mouse assays; low integration was detected at the standard dose and was below assay background at a lower dose.

Mechanism Target:

INHIBITS Repression of Novel Targets Acquired by the Mutant Seed — Allele-specific disruption reduces the mutant product; hearing rescue supports the strategy in +14C>A mice without establishing normalization of every target transcript.

Show evidence (3 references)

PMID:38985856 SUPPORT DIRECT PRIMARY RESULT Model Organism

"we performed editing by nonhomologous DNA end joining (NHEJ) to target a dominant Mir96 mutation"

Defines allele disruption rather than precise repair.

PMID:38985856 SUPPORT DIRECT PRIMARY RESULT Model Organism

"In mice injected at 16 weeks of age, no difference in ABR and DPOAE thresholds was detected"

The late-intervention negative result bounds the treatment window.

PMID:38985856 SUPPORT DIRECT PRIMARY RESULT Model Organism

"there were 102 integration reads, making up 0.26% of the total reads"

The full-text integration result prevents an unqualified claim of no integration from the abstract.

Experimental Amitriptyline

Action: Pharmacotherapy NCIT:C15986

Agent: amitriptyline CHEBI:2666

Platform: Small molecule

Transcriptome-guided selection led to amitriptyline testing in drinking water, beginning with treated breeding parents and continuing in offspring. High-frequency threshold deterioration was temporarily delayed in heterozygotes. Homozygotes did not improve and doubling the dose did not add benefit. The exposure exceeded usual human dosing by body weight, and the authors explicitly did not propose clinical use for DFNA50. The responsible molecular target remains unresolved.

Show evidence (2 references)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"No improvement was seen in the homozygotes drinking amitriptyline"

Preserves the genotype-specific and dose-response limitations.

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"This is a proof of concept rather than a suggestion that amitriptyline be used as a treatment for humans carrying the MIR96+14C>A mutation, for several reasons."

Explicitly limits the result to preclinical proof of concept.

🔬

Diagnosis

1

Audiologic and Molecular Diagnosis

Assess bilateral thresholds, frequency configuration, speech understanding, onset, progression, vestibular symptoms and family history. Use a hearing-loss multigene panel or genomic testing with confirmed coverage of the noncoding MIR96 precursor, followed by pathogenicity interpretation. Coding-exon-focused assays can miss this locus. A pathogenic or likely pathogenic variant consistent with the phenotype supports diagnosis; a VUS alone does not. Once established, a familial variant permits targeted testing of relatives.

Show evidence (4 references)

PMID:22038834 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We screened 882 NSHL patients and 836 normal-hearing Italian controls and identified one putative novel mutation within the miR-96 gene in a family with autosomal dominant NSHL."

Targeted screening of miRNA loci found the Italian allele in a mixed sporadic/familial hearing-loss cohort.

PMID:20186779 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We extended our study to include the miR-183 genes themselves and 24 additional predicted target genes of the miRNA-183 cluster."

The same approach applied to a second cohort, and the reason a negative MIR96 result is informative: this region has been looked at systematically.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"A multigene hearing loss panel ... can often identify the cause of genetic hearing loss while limiting identification of pathogenic variants and variants of uncertain significance in genes that are irrelevant to the underlying phenotype"

General genetic hearing-loss testing guidance applies to the heterogeneous differential.

+ 1 more reference

📈

Progression

2

Presymptomatic carrier stage

Normal hearing before onset is documented among young carriers in the Italian family. Its duration and eventual penetrance are uncertain; a normal early hearing assessment does not exclude later progression.

Show evidence (1 reference)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/ SUPPORT DIRECT PRIMARY RESULT Human Clinical

"all non-penetrants are below the average age of onset of the disease among affected relatives"

Normal hearing at ascertainment does not resolve eventual penetrance.

Progressive hearing loss

Clinical progression occurs over years to decades. In the Italian proband, mild loss around 25 years became severe by 45 and profound in the sixth decade; that trajectory is not a rate estimate for all alleles.

Show evidence (1 reference)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/ SUPPORT DIRECT PRIMARY RESULT Human Clinical

"slowly progressed first to a severe form at the age of 45 and then to a profound form in the sixth decade"

Longitudinal history of the Italian proband.

📊

Prevalence

1

Worldwide

Cases In Literature

No population prevalence estimate is supplied. The September 2023 ClinGen curation included three variants in three probands from two publications, representing the founding Spanish and Italian pedigrees. The Italian study screened 882 genetically undiagnosed hearing-loss patients; the separate American/Iranian family screen found no causal miRNA variant. These selected cohorts do not establish a population prevalence band.

Show evidence (4 references)

PMID:22038834 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We screened 882 NSHL patients and 836 normal-hearing Italian controls and identified one putative novel mutation within the miR-96 gene in a family with autosomal dominant NSHL."

One family identified among 882 selected undiagnosed patients; this is an ascertainment denominator, not population prevalence.

PMID:20186779 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Screening these miRNAs and target sequences in numerous families segregating either autosomal dominant non-syndromic deafness (ADNSHL) or ARNSHL did not identify any potential deafness-causing mutations."

A second screen with no further MIR96 families found.

PMID:20186779 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"These results suggest that mutations disrupting gene regulation by the miR-183 cluster are not a common cause of human hearing loss."

The authors' own conclusion about how rare this class of allele is.

+ 1 more reference

📊

Related Datasets

2

A Cell Type-Specific Approach to Elucidate the Role of miR-96 in Inner Ear Hair Cells geo:GSE255796

mouse BULK RNA SEQ

PMID:38826689

P1 bulk RNA-seq of FACS-isolated hair cells from cochlear and vestibular organs combined, with three mice per genotype (wild type, heterozygous and homozygous diminuendo). This supports cell-type enrichment, not cochlear-only or single-cell resolution. The publication reports a broad maturation-gene signature; an allele-specific Clic5 conclusion would require inspection of the gene-level data.

Show evidence (1 reference)

PMID:38826689 SUPPORT DIRECT PRIMARY RESULT Model Organism

"An important limitation of this study is the inclusion of both cochlear and vestibular HCs to generate the RNA for bulk sequencing."

Defines the sampled cell population.

Therapeutic Restoration of miR-96 Prevents Hearing Loss in Mice through Modulation of Noise-Induced and Genetic Pathways geo:GSE247473

mouse BULK RNA SEQ

PMID:40641557

Whole-cochlea transcriptomes from P28 constitutive Mir96 knockout versus wild-type mice (four per group), and adult inducible knockout versus control mice four weeks after tamoxifen (four knockout and three control samples). The paper also reports AAV rescue experiments, but those interventions are not the RNA-seq comparisons described here. Loss-of-function comparators do not reproduce the acquired target set of dominant seed variants.

Show evidence (1 reference)

PMID:40641557 SUPPORT DIRECT PRIMARY RESULT Model Organism

"The RNA-seq raw data as well as gene read counts for individual sample are accessible at Gene Expression Omnibus under accession number GSE247473."

Verifies the accession-publication link; methods define the two knockout comparisons.

🐁

Animal Models

5

diminuendo (Mir96 Dmdo) ENU seed-mutant mouse

ENU-derived Mir96 +15A>T seed mutant, distinct from the human alleles. Heterozygotes develop severe early auditory impairment and later hair-cell loss; homozygotes have profound impairment and complete neonatal maturation arrest. Transcriptomic motif enrichment supports both lost normal targeting and acquired targeting, subsequently also demonstrated in the human-seed knock-in models.

Species

Mouse

Genotype

Mir96 Dmdo (ENU-induced single-base substitution in the miR-96 seed region), heterozygous and homozygous

Background

C3HeB/FeJ

Genes

MIR96 hgnc:31648

Publication

PMID:19363478

Pathograph links

Repression of Novel Targets Acquired by the Mutant Seed partially recapitulates fidelity: moderate Diminuendo transcriptomes support an acquired-target signature alongside derepression of normal targets; the exact acquired repertoire is allele-specific.

Limitations: The seed position mutated in diminuendo is not one of the two positions mutated in human DFNA50 families, so the specific set of acquired targets is allele-specific and need not match a human carrier's. Enrichment of mutant-seed matches in human and rat orthologues of the downregulated genes was reported as barely above the significance threshold, unlike the wild-type-seed signal, so the acquired target set is the less conserved half of the mechanism.

Readouts

Enrichment of the mutant-seed heptamer among downregulated 3-prime UTRs

Direction: INCREASED

Interpretation: Transcripts carrying a match to the mutant seed are preferentially downregulated, which is what novel targeting predicts.

Show evidence (1 reference)

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Different genes, with target sites complementary to the mutant seed, were downregulated."

The measurement itself.

Show evidence (1 reference)

PMID:33318051 SUPPORT DIRECT PRIMARY RESULT Model Organism

"is likely to be mediated by the gain of novel target genes in addition to the loss of its normal targets"

Establishes that this model is informative for the novel-target node specifically, by contrasting it against null alleles that lack that component.

Impaired Hair Cell Maturation partially recapitulates fidelity: moderate Single-cell physiology establishes neonatal maturation arrest in homozygotes, with an intermediate heterozygous phenotype. This is one component of miR-96 biology rather than proof of an exclusively developmental human disorder.

Limitations: Complete maturation arrest was characterized in neonatal homozygous mice; heterozygotes show intermediate changes. The reported human families carry heterozygous alleles and develop postlingual hearing loss, so neonatal mouse timing is not established human natural history.

Readouts

Biophysical differentiation of inner versus outer hair cells

Direction: ABOLISHED

Interpretation: Homozygous mutant cells retain immature biophysical properties; heterozygotes have intermediate defects.

Show evidence (1 reference)

PMID:21245307 SUPPORT DIRECT PRIMARY RESULT Model Organism

"We found that the physiological development of mutant sensory hair cells is arrested at around the day of birth, before their biophysical differentiation into inner and outer hair cells."

The readout and its direction.

Auditory brainstem or compound action potential threshold

Direction: INCREASED

Interpretation: Thresholds rise by about 60 dB in heterozygotes - a higher threshold means worse hearing - and no response is obtainable in homozygotes.

Show evidence (1 reference)

PMID:19363478 SUPPORT DIRECT PRIMARY RESULT Model Organism

"in heterozygotes thresholds were raised by around 60dB"

The functional readout in the genotype that corresponds to a human carrier.

Show evidence (1 reference)

PMID:21245307 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Moreover, maturation of the hair cell stereocilia bundle and remodelling of auditory nerve connections within the cochlea fail to occur in miR-96 mutants."

Supports treating this model as informative for the maturation-arrest node.

Mir96 +14C>A human-allele knock-in mouse

Knock-in of the human +14C>A allele from Spanish family s1334. Heterozygotes develop progressive high-frequency-first hearing loss and bundle abnormalities; homozygotes are profoundly impaired. This line supports editing and pharmacological proof-of-concept studies, with species and C57BL/6N background limitations.

Species

Mouse

Genotype

Mir96 tm3.1Wtsi (Mir96 +14C>A knock-in), heterozygous and homozygous

Background

C57BL/6N

Genes

MIR96 hgnc:31648

Publication

PMID:39434156

Pathograph links

Stereociliary Bundle Dysfunction partially recapitulates fidelity: moderate Some heterozygous OHC bundles adopt a U shape. The human variant is matched, but human stereociliary anatomy was not measured, so anatomical fidelity remains uncertain.

Limitations: Bundle scoring was qualitative. The C57BL/6N background carries its own age-related hearing-loss allele; a background effect on the +14C>A bundle phenotype was not tested. The separate +13G>A heterozygote retained normal thresholds on both inbred and mixed backgrounds.

Readouts

Outer hair cell stereociliary bundle shape

Direction: ALTERED

Interpretation: Bundles adopt a U shape instead of the mature V.

Show evidence (1 reference)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"In Mir96+14C>A heterozygotes, which have mild hearing loss by P28, some OHC stereocilia bundles have a U-shape, instead of the typical V-shape observed in wildtypes"

The morphological readout and the age at which it is present.

Show evidence (1 reference)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"In Mir96+14C>A heterozygotes, which have mild hearing loss by P28, some OHC stereocilia bundles have a U-shape, instead of the typical V-shape observed in wildtypes"

The same lesion reproduced by a knock-in of an actual human DFNA50 allele rather than the ENU allele.

Progressive Sensorineural Hearing Loss recapitulates fidelity: high Heterozygotes lose hearing progressively from four weeks, starting at high frequencies and spreading, which is the same shape of course as the human disease.

Limitations: The mouse course runs over weeks and the human course over years to decades. Profound homozygous impairment from four weeks does not model the heterozygous genotypes in the founding human families.

Readouts

ABR and DPOAE thresholds across frequency and age

Direction: INCREASED

Interpretation: Thresholds rise - worse hearing - beginning at 32 kHz at four weeks and extending to other frequencies by 8 and 12 weeks.

Show evidence (1 reference)

PMID:38985856 SUPPORT DIRECT PRIMARY RESULT Model Organism

"These results showed that Mir9614C>A/+ mice exhibit hearing loss starting at 4 weeks at the high frequency of 32 kHz, which becomes progressive with further elevation of ABR/DPOAE thresholds at 8 and 12 weeks across other frequencies."

The progressive, high-frequency-first threshold elevation.

Show evidence (1 reference)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Mir96+14C>A heterozygous mice have mild progressive hearing loss most pronounced at high frequencies and progressing with age to lower frequencies"

Direct positive result supports the model-endpoint relation.

Progressive Sensorineural Hearing Loss rescues fidelity: moderate Two independent preclinical rescue arms have been run in this line. AAV delivery of SaCas9-KKH with a guide RNA against the mutant allele into the cochleae of presymptomatic and symptomatic adult mice improved hearing long term, with better results from earlier injection. Separately, amitriptyline - selected by matching the mutant transcriptome against anti-correlated drug expression profiles - delayed progression at high frequencies.

Limitations: Both interventions remain preclinical. Editing disrupts the mutant allele, preserves surviving cells and is ineffective when delivered at sixteen weeks. Low standard-dose vector integration and assay-limited off-target results do not establish human safety. Amitriptyline exposure began with breeding parents and continued in offspring, delayed progression only temporarily, did not improve homozygotes and showed no additional benefit at double dose; the authors did not recommend it for human treatment.

Readouts

Hearing preservation after adult cochlear AAV-SaCas9-KKH editing

Direction: DECREASED

Interpretation: ABR and DPOAE thresholds were lower than untreated contralateral ears after early treatment, representing partial hearing preservation rather than normalization.

Show evidence (1 reference)

PMID:38985856 SUPPORT DIRECT PRIMARY RESULT Model Organism

"AAV delivery of the KKH variant of Staphylococcus aureus Cas9 (SaCas9-KKH) and sgRNA to the cochleae of presymptomatic (3-week-old) and symptomatic (6-week-old) adult Mir9614C>A/+ mutant mice improved hearing long term, with efficacy increased by injection at a younger age."

The rescue result and its dependence on timing.

High-frequency threshold progression under oral amitriptyline

Direction: ALTERED

Interpretation: Progression is delayed rather than halted or reversed, which is why the direction is ALTERED and not RESTORED.

Show evidence (1 reference)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"We chose amitriptyline to test and found that it delays the progression of hearing impairment in Mir96+14C>A heterozygotes"

The pharmacological result, stated as a delay.

Show evidence (1 reference)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"This is a proof of concept rather than a suggestion that amitriptyline be used as a treatment for humans carrying the MIR96+14C>A mutation, for several reasons."

The authors' own statement of how far the rescue claim reaches. Recorded on the link so the RESCUES relationship cannot be read as a therapy claim.

Mir96 +13G>A human-allele knock-in mouse

The +13G>A human-seed knock-in has normal heterozygous ABR thresholds to one year on C57BL/6N despite subtle OHC bundle defects. A mixed-background cohort remained without a threshold phenotype to six months. Homozygotes have profound impairment and reduced IHC synaptic puncta, illustrating the limits of transferring homozygous mouse findings to human heterozygotes.

Species

Mouse

Genotype

Mir96 tm2.1Wtsi (Mir96 +13G>A knock-in), heterozygous and homozygous

Background

C57BL/6N, and a 50 percent C3HeB/FeJ mixed background

Genes

MIR96 hgnc:31648

Publication

PMID:39434156

Pathograph links

Progressive Sensorineural Hearing Loss fails to recapitulate fidelity: low Heterozygotes fail to reproduce the human hearing-threshold phenotype: ABR thresholds remain normal to one year on the tested inbred background and to six months on the mixed background. The tested noise exposure did not uncover a genotype-dependent threshold difference; subtle bundle abnormalities nevertheless occur.

Limitations: The heterozygote fails to reproduce the human threshold phenotype, but remains informative about species- and target-dependent effects. Subtle bundle pathology coexists with normal thresholds. Homozygous synaptic findings do not establish a synaptic lesion in human carriers.

Readouts

ABR threshold in heterozygotes to one year

Direction: UNCHANGED

Interpretation: A real negative result: thresholds do not differ from wild type, so the model carries a human dominant allele without the human dominant phenotype.

Show evidence (1 reference)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"while Mir96+13G>A heterozygotes have normal ABR thresholds"

The negative readout itself.

Show evidence (1 reference)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"While the Mir96+14C>A heterozygotes mimic the phenotype observed in the family with the equivalent mutation, the Mir96+13G>A heterozygotes escape deafness while the same mutation causes progressive hearing loss in humans"

The authors stating the human-model mismatch directly, which is the substantive negative claim this link records.

Inner Hair Cell Synaptic Dysfunction partially recapitulates fidelity: moderate Homozygotes have fewer colocalized IHC synaptic puncta at four weeks; this measured synaptic phenotype differs from the +14C>A comparison.

Limitations: Only the homozygote shows the synaptic deficit, so the finding does not describe the genotype human patients carry. Because the two knock-in lines diverge this much, a programme change measured in this line cannot be assumed to hold for +14C>A or for the diminuendo allele.

Readouts

Colocalised pre- and postsynaptic densities per inner hair cell

Direction: DECREASED

Interpretation: Fewer intact ribbon synapses per inner hair cell in homozygotes.

Show evidence (1 reference)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"In Mir96+13G>A homozygotes, we found significantly fewer colocalised pre- and postsynaptic densities per IHC, indicating synaptic defects"

The synaptic readout and its direction.

Show evidence (1 reference)

PMID:39434156 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Investigations of the structural phenotype showed that one mutation appears to lead to synaptic defects, while the other has a much more severe effect on the hair cell stereociliary bundles."

Establishes that this line is informative for a different arm of the programme than its sibling, which is what PARTIALLY_RECAPITULATES records.

Mir183/96 double-knockout mouse

Deletion of Mir183 and Mir96 provides a loss-of-function comparator. Heterozygous hearing thresholds resemble wild type through six months; homozygotes have profound hearing loss, bundle abnormalities and reduced IHC synapses. Comparing this model with seed mutants supports an acquired-target contribution, with co-deletion, strain and expression-platform confounding.

Species

Mouse

Genotype

Mir183/96 null (Mir183 and Mir96 deleted together), heterozygous and homozygous

Background

C57BL/6N

Genes

MIR96 hgnc:31648 MIR183 hgnc:31554

Publication

PMID:33318051

Pathograph links

Repression of Novel Targets Acquired by the Mutant Seed fails to recapitulate fidelity: low The deleted allele cannot produce a mutant seed RNA. Normal heterozygous hearing argues against simple dosage insufficiency in this model but does not resolve the mechanism of every human precursor allele.

Limitations: The deletion removes Mir183 as well as Mir96, so a comparison against a seed mutant confounds the two microRNAs; and the transcriptomes were compared across studies rather than in one experiment. The conclusion is an inference from a phenotype and transcriptome contrast, not a direct demonstration that any particular acquired target drives the disease.

Readouts

Hearing in null heterozygotes

Direction: UNCHANGED

Interpretation: Normal heterozygous thresholds support a mechanism beyond reduced dosage for dominant seed alleles; they do not prove that partial loss of normal targeting is irrelevant.

Show evidence (1 reference)

PMID:33318051 SUPPORT DIRECT PRIMARY RESULT Model Organism

"We found that Mir183/96 heterozygous mice had normal hearing and homozygotes were completely deaf with abnormal hair cell stereocilia bundles and reduced numbers of inner hair cell synapses at four weeks old."

The negative heterozygous result together with the homozygous phenotype.

Show evidence (1 reference)

PMID:33318051 SUPPORT DIRECT PRIMARY RESULT Model Organism

"We propose three mechanisms of action of mutant miRNAs; loss of targets that are normally completely repressed, loss of targets whose transcription is normally buffered by the miRNA, and gain of novel targets."

The framework this model was built to test, and the reason a failure to recapitulate here is informative rather than a dead end.

Constitutive and Adult-Inducible Mir96 Knockout Mice

Single-gene loss-of-function comparators. Constitutive heterozygotes retained normal hearing through three months, whereas homozygotes progressively lost hearing. Adult biallelic inducible deletion caused hearing loss four weeks after tamoxifen at five months, without detectable cell loss at that time. HC-specific, but not SGN-specific, conditional deletion reproduced the early hearing defect. Neonatal AAV8-miR-96 delivery partially rescued null mice; sustained benefit remained in only a subset, and this was not a test of rescue of a dominant seed variant.

Species

Mouse

Genotype

Mir96 null or UBC CreERT2/+; Mir96 fl/fl

Background

C57BL/6J

Genes

MIR96 hgnc:31648

Publication

PMID:40641557

Pathograph links

Impaired Adult Hair Cell Maintenance perturbs fidelity: moderate Adult deletion tests the maintenance requirement separately from congenital maturation effects.

Limitations: Deletion lacks a mutant target repertoire; the adult inducible driver is systemic, and transcriptomes use mixed whole-cochlear tissue. These experiments do not model dominant human alleles.

Readouts

ABR thresholds after adult Mir96 deletion

Direction: INCREASED

Interpretation: Hearing thresholds rise after adult depletion, before detectable hair-cell or SGN loss.

Show evidence (1 reference)

PMID:40641557 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Hearing loss in the inducible miR-96 knockout mice is likely due to impaired HC function, as HC and SGN numbers were unchanged"

Adult induced deletion separates loss of function from earlier developmental arrest and cell loss.

Show evidence (2 references)

PMID:40641557 SUPPORT DIRECT PRIMARY RESULT Model Organism

"significant hearing loss was observed at 4 weeks after last injection"

The adult-inducible deletion demonstrates a post-developmental requirement.

+ 1 more reference

{ }

Source YAML

click to show

name: Autosomal Dominant Nonsyndromic Hearing Loss 50
category: Mendelian
creation_date: '2026-09-01T00:00:00Z'
synonyms:
- DFNA50
- autosomal dominant deafness 50
- autosomal dominant nonsyndromic deafness 50
- autosomal dominant nonsyndromic deafness type 50
- deafness, autosomal dominant 50
- deafness, autosomal dominant type 50
- MIR96-related hearing loss
description: 'DFNA50 is MIR96-associated autosomal dominant, usually postlingual progressive sensorineural hearing loss. The founding reports describe two Spanish families with seed-region substitutions and an Italian family with a precursor-hairpin substitution. Hearing loss is bilateral; onset, progression and vestibular symptoms vary across families. ClinGen classified the gene-disease relationship as Moderate in September 2023.

  MIR96 encodes a microRNA in the MIR183/MIR96/MIR182 cluster. The human alleles historically designated +13G>A and +14C>A alter the mature miR-96-5p seed and impair its biogenesis in transfected cells. Mouse transcriptomes support both loss of normal target repression and acquisition of allele-specific targets. The Italian +57T>C allele preserves the miR-96-5p sequence but impairs precursor processing and changes the companion miR-96-3p seed; its complete functional effect cannot be reduced to a purely quantitative defect.

  Model studies show disrupted hair-cell maturation, stereociliary and synaptic function, and later degeneration. Adult inducible deletion also demonstrates a maintenance requirement. These findings support an allele-dependent regulatory mechanism, but complete neonatal maturation arrest in homozygous diminuendo mice is not an established universal lesion in human carriers. Standard care addresses hearing and communication needs. Mutant-allele editing and pharmacological rescue remain preclinical approaches in the reviewed sources.'
disease_term:
  preferred_term: autosomal dominant nonsyndromic hearing loss 50
  term:
    id: MONDO:0013114
    label: autosomal dominant nonsyndromic hearing loss 50
parents:
- Autosomal Dominant Nonsyndromic Hearing Loss
inheritance:
- name: Autosomal dominant
  description: Heterozygous MIR96 substitutions segregate with progressive hearing loss in the founding Spanish and Italian families. Each child has a 50% chance of inheriting the causal allele; age-specific penetrance and severity remain uncertain. Normal hearing in heterozygous mouse deletion models informs mechanism but does not establish that dosage effects are irrelevant to every human allele.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:19363479
    reference_title: Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss
    explanation: The inheritance mode as established in the two founding families.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:22038834
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We screened 882 NSHL patients and 836 normal-hearing Italian controls and identified one putative novel mutation within the miR-96 gene in a family with autosomal dominant NSHL.
    explanation: An independent dominant pedigree, and the screening denominator behind it.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic variant to each child.
    explanation: General Mendelian transmission counseling; penetrance and onset remain separate questions.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
pathophysiology:
- name: MIR96 Seed-Region Point Mutation
  biological_scale: MOLECULAR
  description: Heterozygous germline substitutions historically designated +13G>A and +14C>A segregated with hearing loss in two Spanish families. They affect the seed of mature miR-96-5p, altering target recognition; transfected HeLa cells also showed reduced mature miRNA accumulation. The mouse diminuendo +15A>T seed allele is distinct from these human variants.
  genes:
  - preferred_term: MIR96
    term:
      id: hgnc:31648
      label: MIR96
  genetic_context:
    genes:
    - preferred_term: MIR96
      term:
        id: hgnc:31648
        label: MIR96
    allele_type: single-nucleotide substitution within the seed region of the mature miR-96 strand
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    description: Carriers are heterozygous. The two reported human seed alleles are +13G>A and +14C>A in the historical precursor-relative numbering used by the founding papers.
    notes: Historical precursor-relative allele notation is retained. Altered target specificity and reduced miRNA abundance are separate consequences; a single loss-of-function category would not capture both.
    variant_type: single nucleotide variant
    genomic_contexts:
    - noncoding exon
  evidence:
  - reference: PMID:19363479
    reference_title: Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss
    explanation: The initiating lesion is supported by the founding human pedigrees.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:19363479
    reference_title: Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The identified mutations have a strong impact on miR-96 biogenesis and result in a significant reduction of mRNA targeting.
    explanation: Biogenesis and target-repression assays of human alleles, rather than measurements in patient cochlear tissue.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  downstream:
  - target: Loss of Repression of Normal miR-96 Targets
  - target: Repression of Novel Targets Acquired by the Mutant Seed
  mechanism_confidence: ESTABLISHED
- name: MIR96 Precursor Processing Defect
  biological_scale: MOLECULAR
  description: The Italian +57T>C substitution lies in the precursor hairpin and the companion miR-96* (miR-96-3p) seed, while preserving the mature miR-96-5p sequence. In HeLa cells, mature miR-96 and miR-96* fell by approximately 85% and 77%, respectively, without reduced precursor abundance. A compensatory +23A>G change restored pairing, mature levels and MYRIP reporter repression. These results support defective processing, with impaired Dicer cleavage proposed rather than directly assayed. Altered targeting by the changed companion seed remains possible; it was not established by the tested reporters.
  biological_processes:
  - preferred_term: miRNA processing
    modifier: DECREASED
    term:
      id: GO:0035196
      label: miRNA processing
  genes:
  - preferred_term: MIR96
    term:
      id: hgnc:31648
      label: MIR96
  genetic_context:
    genes:
    - preferred_term: MIR96
      term:
        id: hgnc:31648
        label: MIR96
    allele_type: single-nucleotide substitution in the pre-miR-96 hairpin, within the miR-96* strand
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    description: Historical +57T>C allele changes precursor pairing and the miR-96-3p seed, while the miR-96-5p sequence is unchanged.
    variant_type: single nucleotide variant
    genomic_contexts:
    - noncoding exon
  evidence:
  - reference: PMID:22038834
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: Although located outside the mature miR-96 sequence, the detected variant replaces a highly conserved nucleotide within the companion miR-96*, and is predicted to reduce the stability of the pre-miRNA hairpin.
    explanation: The location of the variant and the structural prediction. Graded COMPUTATIONAL because the destabilisation claim in this sentence is a secondary-structure prediction; the functional confirmation is quoted separately below.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:22038834
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that both miR-96 and miR-96* levels were significantly reduced in the mutant, whereas the precursor levels were unaffected.
    explanation: Reduced mature products despite preserved precursor abundance support impaired processing rather than reduced precursor production.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:22038834
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: demonstrating that the mutation hinders precursor processing, probably interfering with Dicer cleavage
    explanation: The study concludes that processing is impaired; Dicer cleavage is proposed rather than directly measured.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing - PMC
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: In particular, the change occurs at position +6, within the miR-96* seed region
    explanation: The companion strand also has a seed alteration, precluding the claim that the allele cannot change target specificity.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing - PMC
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: the precursor levels were unaffected by the mutation
    explanation: The HeLa assay localizes the abundance defect downstream of precursor accumulation.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing - PMC
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: the mutant showed a significant reduction in mature miR-96
    explanation: The +13G>A comparison reduced miR-96 while sparing miR-96*; the two allele classes need not share one processing mechanism.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Loss of Repression of Normal miR-96 Targets
  mechanism_confidence: PROVISIONAL
- name: Loss of Repression of Normal miR-96 Targets
  biological_scale: MOLECULAR
  description: Loss of normal miR-96-mediated repression raises expression of some wild-type targets. Wild-type seed matches are enriched among upregulated transcripts in diminuendo and both human-seed knock-in mouse transcriptomes. Human-allele reporter assays support impaired repression, but expression and target repertoires in human cochlear hair cells have not been directly measured in these studies.
  biological_processes:
  - preferred_term: miRNA-mediated post-transcriptional gene silencing of the wild-type miR-96 target set
    modifier: DECREASED
    term:
      id: GO:0035195
      label: miRNA-mediated post-transcriptional gene silencing
  notes: CLIC5 is a direct target in HEI-OC1 mimic/reporter experiments. Clic5 increases in the P1 cochlea of whole-cluster knockout mice and is among the upregulated transcripts in P28 single-Mir96-knockout cochlea. These results do not establish its direction or causal contribution in human seed-variant DFNA50; cellular composition, allele and developmental stage differ. Biallelic CLIC5 loss in DFNB103 is a distinct lesion.
  evidence:
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Hypergeometric P-value analysis showed that hundreds of genes were upregulated in mutants.
    explanation: 'The scale of de-repression in the diminuendo organ of Corti: hundreds of genes rise, which is what loss of normal targeting predicts.'
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: This indicates that miR-96 normally modulates expression of a broad range of target genes, and that it affects mRNA levels rather than affecting translation alone.
    explanation: 'The Sylamer conclusion: the upregulated set carries wild-type miR-96 seed matches, so the effect is on this specific target set rather than a general one, and it is measurable as transcript abundance.'
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:19363479
    reference_title: Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The identified mutations have a strong impact on miR-96 biogenesis and result in a significant reduction of mRNA targeting.
    explanation: Biogenesis and target-repression assays of human alleles, rather than measurements in patient cochlear tissue.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:22889583
    reference_title: MiR-183 family regulates chloride intracellular channel 5 expression in inner ear hair cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: INDIRECT
    snippet: Our findings thus suggest that CLIC5 is directly regulated by miR-96 and miR-182 and that the target sequence in this regard is located between nucleotides 760-766 within the CLIC5 3'-UTR.
    explanation: Establishes CLIC5 as a member of the normal miR-96 target set, mapped to a specific site. Indirect for this node because it is a cell-line experiment on wild-type miR-96, not a measurement in a DFNA50 genotype.
    quote_role: PRIMARY_RESULT
  - reference: PMID:30575790
    reference_title: The microRNA-183/96/182 Cluster is Essential for Stereociliary Bundle Formation and Function of Cochlear Sensory Hair Cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: INDIRECT
    snippet: Several predicted target genes of the miR-183/96/182 cluster that are known to play important roles in HC development and function, including Clic5, Rdx, Ezr, Rac1, Myo1c, Pvrl3 and Sox2, are upregulated in the cochlea.
    explanation: In vivo confirmation that losing cluster function de-represses this target set, Clic5 included, and the direction it moves. Indirect because the model is a gene-trap null of the whole cluster, not a miR-96 seed mutation.
    quote_role: PRIMARY_RESULT
  - reference: PMID:39434156
    reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the complementary heptamer to the miR-96 seed region (GTGCCAA, red line) was greatly enriched in the 3′UTRs of hundreds of genes upregulated in Mir96+13G>A and Mir96+14C>A homozygotes
    explanation: Both human-seed knock-in transcriptomes reproduce the wild-type target-loss signature.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Dysregulation of the Hair Cell Maturation Gene Programme
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
  mechanism_confidence: PROVISIONAL
- name: Repression of Novel Targets Acquired by the Mutant Seed
  biological_scale: MOLECULAR
  description: A changed miR-96-5p seed can acquire a different target repertoire. Mutant-seed matches are enriched among downregulated transcripts in diminuendo and both human-seed knock-in lines. Normal hearing thresholds in heterozygous deletion models support a contribution from mutant RNA beyond reduced normal dosage, but do not exclude quantitative effects for every human allele. The acquired targets depend on allele and species.
  biological_processes:
  - preferred_term: miRNA-mediated post-transcriptional gene silencing of transcripts complementary to the mutant seed
    term:
      id: GO:0035195
      label: miRNA-mediated post-transcriptional gene silencing
  notes: Target-set specificity is described separately from quantitative changes in gene silencing. Motif enrichment supports acquired targeting across a transcriptome; it does not validate every predicted individual target.
  evidence:
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Different genes, with target sites complementary to the mutant seed, were downregulated.
    explanation: 'The direct transcriptomic signature of novel targeting: genes bearing the mutant seed match are the ones that go down, and they are a different set from the genes that carry wild-type sites.'
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: indicating that mutant miR-96 influences expression of newly-acquired target genes
    explanation: The authors' reading of that enrichment, stated as acquisition of new targets.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the phenotype results from a lack of repression of normal targets even though we show a gain of repression of novel targets
    explanation: The founding mouse paper's own weighting of the two halves, which at that time put the abandoned targets first. Recorded because the weighting later shifted, and both readings should be visible.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:33318051
    reference_title: Hearing impairment due to Mir183/96/182 mutations suggests both loss and gain of function effects.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We propose three mechanisms of action of mutant miRNAs; loss of targets that are normally completely repressed, loss of targets whose transcription is normally buffered by the miRNA, and gain of novel targets.
    explanation: The explicit three-mechanism account. It is the reason this entry splits the target repertoire into two nodes rather than collapsing it into one dysregulation node.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:33318051
    reference_title: Hearing impairment due to Mir183/96/182 mutations suggests both loss and gain of function effects.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: is likely to be mediated by the gain of novel target genes in addition to the loss of its normal targets
    explanation: The seed-mutant versus deletion comparison supports a novel-target contribution, with background, platform and co-deletion differences limiting attribution.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:39434156
    reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Neither of the mutant seed regions is enriched in the other mutant
    explanation: The two human-seed knock-ins have allele-specific acquired-target signatures.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Dysregulation of the Hair Cell Maturation Gene Programme
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
  mechanism_confidence: PROVISIONAL
- name: Dysregulation of the Hair Cell Maturation Gene Programme
  biological_scale: CELLULAR
  description: Altered miRNA targeting changes a broad hair-cell gene program. In the original P4 diminuendo organ-of-Corti experiment, Slc26a5, Ocm, Gfi1, Ptprq and Pitpnm1 were strongly downregulated. Only Ocm and prestin staining was compared with nine other deaf mutants. The original prediction analysis did not identify miR-96 sites in these five genes, but later work identified a potential diminuendo-specific site in Ptprq. Their regulation therefore cannot all be assigned to one proven indirect route. P1 sorted hair-cell RNA-seq and human-seed knock-in transcriptomes support widespread, allele-dependent changes.
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  - preferred_term: cochlear outer hair cell
    term:
      id: CL:0000601
      label: cochlear outer hair cell
  locations:
  - preferred_term: organ of Corti
    term:
      id: UBERON:0002227
      label: spiral organ of cochlea
  genes:
  - preferred_term: SLC26A5
    term:
      id: hgnc:9359
      label: SLC26A5
  - preferred_term: OCM
    term:
      id: hgnc:8105
      label: OCM
  - preferred_term: GFI1
    term:
      id: hgnc:4237
      label: GFI1
  - preferred_term: PTPRQ
    term:
      id: hgnc:9679
      label: PTPRQ
  - preferred_term: PITPNM1
    term:
      id: hgnc:9003
      label: PITPNM1
  notes: HGNC bindings denote human orthologues of genes measured in mice. Ptprq reduction is a candidate contributor to bundle abnormalities; comparing Ptprq-null and diminuendo mice supports partial phenotypic overlap, not proof that Ptprq alone mediates DFNA50. Sorted P1 RNA-seq mixed cochlear and vestibular hair cells. Supporting-cell gene repression is a proposed explanation, not demonstrated conversion of hair cells to supporting cells.
  evidence:
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Microarray analysis revealed 96 transcripts with significantly altered expression in homozygotes; notably, Slc26a5, Ocm, Gfi1, Ptprq and Pitpnm1 were downregulated.
    explanation: The named downregulated maturation genes and the size of the transcriptional shift.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:24446963
    reference_title: A reduction in Ptprq associated with specific features of the deafness phenotype of the miR-96 mutant mouse diminuendo.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The reduction in Ptprq observed in diminuendo mice appears to be a major contributor to the morphological, transcriptional and electrophysiological phenotype, but does not account for the complete diminuendo phenotype.
    explanation: The comparison supports a partial Ptprq contribution, without a quantitative mediation estimate or a rescue experiment proving the entire causal route.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: url:https://www.ebi.ac.uk/europepmc/webservices/rest/PMC7903918/fullTextXML
    reference_title: ABSTRACT
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: we found 19 genes that were significantly downregulated in the mutant and that bore matches to the mutant seed region in their 3′UTR ... The list includes one known deafness gene, ... Ptprq
    explanation: Hearing impairment due to Mir183/96/182 mutations suggests both loss and gain of function effects. (PMID:33318051; full-text XML; the cache extractor supplies a generic abstract heading as its title.) The full text includes Ptprq among predicted acquired targets, revising the original no-site interpretation.
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:38826689
    reference_title: A cell type-specific approach to elucidate the role of miR-96 in inner ear hair cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: An important limitation of this study is the inclusion of both cochlear and vestibular HCs to generate the RNA for bulk sequencing.
    explanation: Bounds the anatomical scope of the sorted hair-cell transcriptome.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:39434156
    reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The two mutants share only 124 DEGs misregulated in the same direction
    explanation: The human-seed knock-in transcriptomes diverge despite adjacent seed substitutions.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Impaired Hair Cell Maturation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
  - target: Loss of Cochlear Amplification
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
  - target: Impaired Adult Hair Cell Maintenance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
    description: Adult deletion experiments support continued regulatory requirements, but the relevant targets in human seed-variant carriers are unresolved.
  mechanism_confidence: PROVISIONAL
- name: Impaired Hair Cell Maturation
  biological_scale: CELLULAR
  description: Complete functional maturation arrest around birth was demonstrated in homozygous diminuendo mice, with less severe or intermediate abnormalities in heterozygotes. These cells retain immature conductances and synaptic properties. This experiment does not directly establish neonatal maturation arrest in human heterozygous carriers.
  biological_processes:
  - preferred_term: inner ear receptor cell differentiation
    modifier: DECREASED
    term:
      id: GO:0060113
      label: inner ear receptor cell differentiation
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  - preferred_term: cochlear outer hair cell
    term:
      id: CL:0000601
      label: cochlear outer hair cell
  evidence:
  - reference: PMID:21245307
    reference_title: miR-96 regulates the progression of differentiation in mammalian cochlear inner and outer hair cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We found that the physiological development of mutant sensory hair cells is arrested at around the day of birth, before their biophysical differentiation into inner and outer hair cells.
    explanation: The timing and nature of the arrest, from single hair cell electrophysiology.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  downstream:
  - target: Stereociliary Bundle Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
  - target: Inner Hair Cell Synaptic Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
  mechanism_confidence: PROVISIONAL
- name: Stereociliary Bundle Dysfunction
  biological_scale: CELLULAR
  description: Diminuendo mice show immature or disorganized stereociliary bundles, with stronger defects in homozygotes. In +14C>A heterozygous mice some outer hair-cell bundles are rounded; +13G>A heterozygotes lose some shortest-row stereocilia despite normal ABR thresholds. Direct recordings in diminuendo OHCs show reduced mechanotransduction currents and impaired adaptation, while residual currents indicate that transduction is not wholly absent as in the cluster knockout.
  biological_processes:
  - preferred_term: auditory receptor cell stereocilium organization
    modifier: ABNORMAL
    term:
      id: GO:0060088
      label: auditory receptor cell stereocilium organization
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  - preferred_term: cochlear outer hair cell
    term:
      id: CL:0000601
      label: cochlear outer hair cell
  evidence:
  - reference: PMID:21245307
    reference_title: miR-96 regulates the progression of differentiation in mammalian cochlear inner and outer hair cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Moreover, maturation of the hair cell stereocilia bundle and remodelling of auditory nerve connections within the cochlea fail to occur in miR-96 mutants.
    explanation: The two maturation events that fail, stated together.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Remaining outer hair cell stereocilia bundles formed a loose U-shape rather than the precise V-shape of controls
    explanation: Heterozygous diminuendo mice have an abnormal bundle shape; their allele differs from the human variants.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:39434156
    reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In Mir96+14C>A heterozygotes, which have mild hearing loss by P28, some OHC stereocilia bundles have a U-shape, instead of the typical V-shape observed in wildtypes
    explanation: The same lesion reproduced by a knock-in of an actual human DFNA50 allele rather than the ENU allele.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: url:https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4065360/fullTextXML
    reference_title: Abstract
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Slipping and rebound adaptation were largely reduced or absent in heterozygous and homozygous diminuendo P6 OHCs
    explanation: A reduction in Ptprq associated with specific features of the deafness phenotype of the miR-96 mutant mouse diminuendo. (PMID:24446963; full-text XML; the cache extractor supplies a generic abstract heading as its title.) Direct mechanotransduction recordings identify an additional functional defect in diminuendo outer hair cells.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Outer Hair Cell Degeneration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
  - target: Loss of Cochlear Amplification
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
  mechanism_confidence: PROVISIONAL
- name: Impaired Adult Hair Cell Maintenance
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  - preferred_term: cochlear outer hair cell
    term:
      id: CL:0000601
      label: cochlear outer hair cell
  description: Adult inducible biallelic Mir96 deletion impairs hearing before detectable hair-cell or spiral-ganglion loss. Hair-cell-specific constitutive deletion reproduces auditory impairment, whereas the tested SGN-specific deletion does not. These loss-of-function experiments support a continuing requirement for miR-96, distinct from neonatal maturation; how this requirement contributes to dominant human alleles remains uncertain.
  evidence:
  - reference: PMID:40641557
    reference_title: Therapeutic restoration of miR-96 prevents hearing loss in mice through modulation of noise-induced and genetic pathways.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Hearing loss in the inducible miR-96 knockout mice is likely due to impaired HC function, as HC and SGN numbers were unchanged
    explanation: Adult induced deletion separates loss of function from earlier developmental arrest and cell loss.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Loss of Cochlear Amplification
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
    description: Proposed contribution of impaired adult hair-cell function; the inducible study did not isolate every component of the hearing deficit.
- name: Inner Hair Cell Synaptic Dysfunction
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  description: Diminuendo homozygotes retain immature calcium-dependent exocytosis, spherical ribbons and disorganized afferent/efferent connections. The +13G>A homozygous knock-in has fewer colocalized pre- and postsynaptic puncta at four weeks; +14C>A homozygotes did not show the same significant reduction. Synaptic pathology is allele-dependent and has not been demonstrated in human heterozygotes.
  evidence:
  - reference: PMID:21245307
    reference_title: miR-96 regulates the progression of differentiation in mammalian cochlear inner and outer hair cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Moreover, maturation of the hair cell stereocilia bundle and remodelling of auditory nerve connections within the cochlea fail to occur in miR-96 mutants.
    explanation: Auditory nerve connections fail to remodel in diminuendo mutants. The full text adds that the wiring defect might arise in hair cells and/or the peripheral sensory neurons, so the experiment does not uniquely assign it to one cellular compartment.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:39434156
    reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: no significant differences were found in the number of synapses in Mir96+14C>A wildtypes, heterozygotes and homozygotes
    explanation: Preserves the negative comparison rather than universalizing the +13G>A synaptic lesion.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Progressive Sensorineural Hearing Loss
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
- name: Outer Hair Cell Degeneration
  biological_scale: TISSUE
  description: Hair-cell loss contributes to later disease in mouse models even though severe dysfunction can precede it. In heterozygous diminuendo mice, outer hair cells in middle and basal regions degenerate while many inner hair cells remain. The +14C>A model also develops progressive OHC loss, and mutant-allele editing improves survival. These findings support a degenerative component without establishing a uniform human histopathology.
  cell_types:
  - preferred_term: cochlear outer hair cell
    term:
      id: CL:0000601
      label: cochlear outer hair cell
  locations:
  - preferred_term: organ of Corti
    term:
      id: UBERON:0002227
      label: spiral organ of cochlea
  evidence:
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In heterozygotes many outer hair cells had degenerated in the middle and basal turns but most inner hair cells remained intact
    explanation: The cell type and cochlear location of the degeneration in heterozygotes.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: this and previous studies suggest that the degeneration is instead a correlate or consequence of a prior dysfunction of the hair cells
    explanation: The authors' explicit ordering of dysfunction before degeneration, which is what places this node downstream of the maturation nodes rather than upstream of them.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:38985856
    reference_title: Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: improved OHC survival was seen across all frequency regions compared with the uninjected Mir9614C>A/+ mice
    explanation: Intervention in the human-allele model supports preservation of surviving outer hair cells.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Loss of Cochlear Amplification
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
  mechanism_confidence: PROVISIONAL
- name: Loss of Cochlear Amplification
  biological_scale: TISSUE
  description: Reduced expression of prestin and loss or dysfunction of outer hair cells provide plausible routes to impaired active cochlear amplification. Elevated DPOAE thresholds in the +14C>A model support OHC dysfunction. The normal endocochlear potential measured in diminuendo mice argues against a primary strial-potential defect in that experiment; it does not exclude every ionic or strial contribution in human disease.
  cell_types:
  - preferred_term: cochlear outer hair cell
    term:
      id: CL:0000601
      label: cochlear outer hair cell
  evidence:
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Prestin is a voltage-sensitive motor molecule that mediates outer hair cell length changes responsible for amplification of sound within the cochlea
    explanation: Background physiology explains why reduced prestin could impair amplification; it is not a direct amplification measurement in this study.
    quote_role: BACKGROUND
    directness: INDIRECT
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Endocochlear potentials were within the normal range
    explanation: Normal endocochlear potential in the tested diminuendo mice bounds the strial-potential explanation in that model.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:38985856
    reference_title: Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: a 19-dB elevation in DPOAE
    explanation: At four weeks, heterozygous +14C>A mice had elevated 32-kHz DPOAE thresholds, supporting OHC dysfunction.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Progressive Sensorineural Hearing Loss
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - mir96_allele_specific_cochlear_dysfunction
  mechanism_confidence: PROVISIONAL
- name: Progressive Sensorineural Hearing Loss
  biological_scale: ORGANISM
  conforms_to: sensorineural_hair_cell_loss#Progressive Sensorineural Hearing Loss
  description: The human endpoint is progressive bilateral sensorineural hearing loss with variable onset and severity. Mouse threshold abnormalities provide experimental support for a hair-cell mechanism but vary markedly by allele and zygosity. The +13G>A heterozygous model does not reproduce the hearing-threshold phenotype of the corresponding human family.
  notes: Conformance is limited to the hearing-loss endpoint. The reviewed experiments do not justify importing an entire generic oxidative or ionic injury chain into DFNA50.
  evidence:
  - reference: PMID:19363478
    reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: in heterozygotes thresholds were raised by around 60dB
    explanation: The magnitude of the functional deficit in the heterozygous mouse.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:19363479
    reference_title: Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss
    explanation: The human endpoint the mouse deficit corresponds to.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  downstream:
  - target: Progressive Sensorineural Hearing Impairment
  - target: High-Frequency Hearing Impairment
    description: Observed audiometric configuration in the reported families.
  mechanism_confidence: ESTABLISHED
phenotypes:
- name: Progressive Sensorineural Hearing Impairment
  category: Auditory
  description: Progressive sensorineural hearing loss is the core clinical phenotype. Reported onset is generally postlingual, but age, severity and progression vary. In the Italian family onset ranged approximately from 25 to 40 years; the proband progressed from mild loss around 25 to severe loss at 45 and profound loss in the sixth decade.
  phenotype_term:
    preferred_term: Progressive sensorineural hearing impairment
    term:
      id: HP:0000408
      label: Progressive sensorineural hearing impairment
    laterality: BILATERAL
    onset:
      notes: Usually postlingual; adult onset approximately 25–40 years in the Italian precursor-variant family. Normal hearing in young carriers does not establish lifelong nonpenetrance.
  evidence:
  - reference: PMID:19363479
    reference_title: Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss
    explanation: Progression stated in the founding description of the two Spanish families.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:22038834
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Recently, point mutations within the seed region of miR-96 were reported in two Spanish families with autosomal dominant non-syndromic sensorineural hearing loss (NSHL) and in a mouse model of NSHL.
    explanation: The Italian paper recalls the earlier Spanish report; its own proband description below provides direct clinical evidence.
    quote_role: BACKGROUND
    directness: INDIRECT
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing - PMC
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The proband shows non-syndromic, bilateral, sensorineural deafness that onset as a mild hearing impairment at
    explanation: Direct clinical description supports bilaterality and mild initial presentation in the Italian proband.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing - PMC
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: all non-penetrants are below the average age of onset of the disease among affected relatives
    explanation: Normal hearing at ascertainment does not resolve eventual penetrance.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In general, autosomal dominant nonsyndromic hearing loss is postlingual, progressive, and high frequency.
    explanation: General GeneReviews clinical baseline; the family-specific observations above establish the DFNA50 presentation.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  notes: Three normal-hearing children in the Italian family carried the variant and were below the family mean onset age. The report could not distinguish age-dependent expression from incomplete penetrance; an obligate frequency across carriers is not established.
- name: High-Frequency Hearing Impairment
  category: Auditory
  phenotype_term:
    preferred_term: High-frequency hearing impairment
    term:
      id: HP:0005101
      label: High-frequency hearing impairment
  description: High frequencies are prominently affected in the Spanish seed-variant families. The Italian proband had a down-sloping audiogram involving all frequencies. This describes configuration rather than a separate onset phenotype.
  evidence:
  - reference: url:https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_01d1a7f4-8421-4be3-8fe7-2c2025f03ac9-2023-09-26T160000.000Z
    reference_title: curation results for Gene-Disease Validity
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Autosomal dominant, progressive, high-frequency hearing loss.
    explanation: ClinGen summarizes the clinical configuration in the +14C>A family.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing - PMC
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: She presents a down-sloping audiometric profile in which all frequencies are affected
    explanation: The Italian proband had broader frequency involvement.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- name: Episodic Vertigo
  category: Vestibular
  phenotype_term:
    preferred_term: Vertigo
    term:
      id: HP:0002321
      label: Vertigo
  description: Episodes were reported by the proband, her mother and her brother in the Italian +57T>C family. This is a family-specific observation, not a universal DFNA50 manifestation or a demonstrated vestibular cellular mechanism.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing - PMC
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: episodes of vertigo were reported in the proband (III-2), her mother (II-2) and her brother (III-3)
    explanation: Direct human observation supports adding the previously omitted phenotype.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  notes: No population prevalence estimate is supplied. The September 2023 ClinGen curation included three variants in three probands from two publications, representing the founding Spanish and Italian pedigrees. The Italian study screened 882 genetically undiagnosed hearing-loss patients; the separate American/Iranian family screen found no causal miRNA variant. These selected cohorts do not establish a population prevalence band.
  evidence:
  - reference: PMID:22038834
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We screened 882 NSHL patients and 836 normal-hearing Italian controls and identified one putative novel mutation within the miR-96 gene in a family with autosomal dominant NSHL.
    explanation: One family identified among 882 selected undiagnosed patients; this is an ascertainment denominator, not population prevalence.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:20186779
    reference_title: miRNA mutations are not a common cause of deafness.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Screening these miRNAs and target sequences in numerous families segregating either autosomal dominant non-syndromic deafness (ADNSHL) or ARNSHL did not identify any potential deafness-causing mutations.
    explanation: A second screen with no further MIR96 families found.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:20186779
    reference_title: miRNA mutations are not a common cause of deafness.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These results suggest that mutations disrupting gene regulation by the miR-183 cluster are not a common cause of human hearing loss.
    explanation: The authors' own conclusion about how rare this class of allele is.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: url:https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_01d1a7f4-8421-4be3-8fe7-2c2025f03ac9-2023-09-26T160000.000Z
    reference_title: curation results for Gene-Disease Validity
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Three variants (single nucleotide changes in microRNA) that have been reported in three probands in two publications
    explanation: Date-bounded evidence count from the ClinGen curation, not a worldwide incidence estimate.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
progression:
- phase: Presymptomatic carrier stage
  notes: Normal hearing before onset is documented among young carriers in the Italian family. Its duration and eventual penetrance are uncertain; a normal early hearing assessment does not exclude later progression.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing - PMC
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: all non-penetrants are below the average age of onset of the disease among affected relatives
    explanation: Normal hearing at ascertainment does not resolve eventual penetrance.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- phase: Progressive hearing loss
  notes: Clinical progression occurs over years to decades. In the Italian proband, mild loss around 25 years became severe by 45 and profound in the sixth decade; that trajectory is not a rate estimate for all alleles.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3259013/
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing - PMC
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: slowly progressed first to a severe form at the age of 45 and then to a profound form in the sixth decade
    explanation: Longitudinal history of the Italian proband.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
genetic:
- name: MIR96
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  gene_term:
    preferred_term: MIR96
    term:
      id: hgnc:31648
      label: MIR96
  notes: MIR96 is a non-protein-coding microRNA gene at 7q32.2 in the MIR183/MIR96/MIR182 cluster. Pathogenic substitutions can affect the mature miR-96-5p seed or another part of its precursor, including the miR-96-3p seed. Historical +13G>A, +14C>A and +57T>C notation is retained. Sequence conservation permits testing orthologous alleles and guides, but does not ensure conserved target 3-prime UTRs, matching phenotypes or human treatment efficacy. ClinGen classified the dominant hearing-loss association as Moderate in September 2023.
  evidence:
  - reference: PMID:19363479
    reference_title: Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear, result in autosomal dominant, progressive hearing loss
    explanation: The initiating lesion is supported by the founding human pedigrees.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:22038834
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In conclusion, we provide further evidence of the involvement of miR-96 mutations in human deafness and demonstrate that a quantitative defect of this miRNA may contribute to NSHL.
    explanation: Independent replication of the gene-disease relationship in a third family.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:38985856
    reference_title: Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: Because mouse and human MIR96 sequences share 100% homology
    explanation: Sequence conservation supports guide design, but does not by itself establish conservation of downstream targets or human efficacy.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: url:https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_01d1a7f4-8421-4be3-8fe7-2c2025f03ac9-2023-09-26T160000.000Z
    reference_title: curation results for Gene-Disease Validity
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In summary, there is moderate evidence to support this gene-disease relationship.
    explanation: Date-specific expert assessment of the dominant hearing-loss association.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
diagnosis:
- name: Audiologic and Molecular Diagnosis
  description: Assess bilateral thresholds, frequency configuration, speech understanding, onset, progression, vestibular symptoms and family history. Use a hearing-loss multigene panel or genomic testing with confirmed coverage of the noncoding MIR96 precursor, followed by pathogenicity interpretation. Coding-exon-focused assays can miss this locus. A pathogenic or likely pathogenic variant consistent with the phenotype supports diagnosis; a VUS alone does not. Once established, a familial variant permits targeted testing of relatives.
  evidence:
  - reference: PMID:22038834
    reference_title: A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We screened 882 NSHL patients and 836 normal-hearing Italian controls and identified one putative novel mutation within the miR-96 gene in a family with autosomal dominant NSHL.
    explanation: Targeted screening of miRNA loci found the Italian allele in a mixed sporadic/familial hearing-loss cohort.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:20186779
    reference_title: miRNA mutations are not a common cause of deafness.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We extended our study to include the miR-183 genes themselves and 24 additional predicted target genes of the miRNA-183 cluster.
    explanation: 'The same approach applied to a second cohort, and the reason a negative MIR96 result is informative: this region has been looked at systematically.'
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A multigene hearing loss panel ... can often identify the cause of genetic hearing loss while limiting identification of pathogenic variants and variants of uncertain significance in genes that are irrelevant to the underlying phenotype
    explanation: General genetic hearing-loss testing guidance applies to the heterogeneous differential.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The identification of variant(s) of uncertain significance cannot be used to confirm or rule out the diagnosis.
    explanation: Separates variant detection from molecular diagnosis.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
animal_models:
- name: diminuendo (Mir96 Dmdo) ENU seed-mutant mouse
  species: Mouse
  genotype: Mir96 Dmdo (ENU-induced single-base substitution in the miR-96 seed region), heterozygous and homozygous
  background: C3HeB/FeJ
  publication: PMID:19363478
  genes:
  - preferred_term: MIR96
    term:
      id: hgnc:31648
      label: MIR96
  description: ENU-derived Mir96 +15A>T seed mutant, distinct from the human alleles. Heterozygotes develop severe early auditory impairment and later hair-cell loss; homozygotes have profound impairment and complete neonatal maturation arrest. Transcriptomic motif enrichment supports both lost normal targeting and acquired targeting, subsequently also demonstrated in the human-seed knock-in models.
  modeled_mechanisms:
  - target: Repression of Novel Targets Acquired by the Mutant Seed
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: Diminuendo transcriptomes support an acquired-target signature alongside derepression of normal targets; the exact acquired repertoire is allele-specific.
    limitations: The seed position mutated in diminuendo is not one of the two positions mutated in human DFNA50 families, so the specific set of acquired targets is allele-specific and need not match a human carrier's. Enrichment of mutant-seed matches in human and rat orthologues of the downregulated genes was reported as barely above the significance threshold, unlike the wild-type-seed signal, so the acquired target set is the less conserved half of the mechanism.
    readouts:
    - name: Enrichment of the mutant-seed heptamer among downregulated 3-prime UTRs
      target: Repression of Novel Targets Acquired by the Mutant Seed
      direction: INCREASED
      interpretation: Transcripts carrying a match to the mutant seed are preferentially downregulated, which is what novel targeting predicts.
      evidence:
      - reference: PMID:19363478
        reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Different genes, with target sites complementary to the mutant seed, were downregulated.
        explanation: The measurement itself.
        quote_role: PRIMARY_RESULT
        directness: DIRECT
    evidence:
    - reference: PMID:33318051
      reference_title: Hearing impairment due to Mir183/96/182 mutations suggests both loss and gain of function effects.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: is likely to be mediated by the gain of novel target genes in addition to the loss of its normal targets
      explanation: Establishes that this model is informative for the novel-target node specifically, by contrasting it against null alleles that lack that component.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  - target: Impaired Hair Cell Maturation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: Single-cell physiology establishes neonatal maturation arrest in homozygotes, with an intermediate heterozygous phenotype. This is one component of miR-96 biology rather than proof of an exclusively developmental human disorder.
    limitations: Complete maturation arrest was characterized in neonatal homozygous mice; heterozygotes show intermediate changes. The reported human families carry heterozygous alleles and develop postlingual hearing loss, so neonatal mouse timing is not established human natural history.
    readouts:
    - name: Biophysical differentiation of inner versus outer hair cells
      target: Impaired Hair Cell Maturation
      direction: ABOLISHED
      interpretation: Homozygous mutant cells retain immature biophysical properties; heterozygotes have intermediate defects.
      evidence:
      - reference: PMID:21245307
        reference_title: miR-96 regulates the progression of differentiation in mammalian cochlear inner and outer hair cells.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: We found that the physiological development of mutant sensory hair cells is arrested at around the day of birth, before their biophysical differentiation into inner and outer hair cells.
        explanation: The readout and its direction.
        quote_role: PRIMARY_RESULT
        directness: DIRECT
    - name: Auditory brainstem or compound action potential threshold
      target: Impaired Hair Cell Maturation
      direction: INCREASED
      interpretation: Thresholds rise by about 60 dB in heterozygotes - a higher threshold means worse hearing - and no response is obtainable in homozygotes.
      evidence:
      - reference: PMID:19363478
        reference_title: An ENU-induced mutation of miR-96 associated with progressive hearing loss in mice.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: in heterozygotes thresholds were raised by around 60dB
        explanation: The functional readout in the genotype that corresponds to a human carrier.
        quote_role: PRIMARY_RESULT
        directness: DIRECT
    evidence:
    - reference: PMID:21245307
      reference_title: miR-96 regulates the progression of differentiation in mammalian cochlear inner and outer hair cells.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Moreover, maturation of the hair cell stereocilia bundle and remodelling of auditory nerve connections within the cochlea fail to occur in miR-96 mutants.
      explanation: Supports treating this model as informative for the maturation-arrest node.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
- name: Mir96 +14C>A human-allele knock-in mouse
  species: Mouse
  genotype: Mir96 tm3.1Wtsi (Mir96 +14C>A knock-in), heterozygous and homozygous
  background: C57BL/6N
  publication: PMID:39434156
  genes:
  - preferred_term: MIR96
    term:
      id: hgnc:31648
      label: MIR96
  description: Knock-in of the human +14C>A allele from Spanish family s1334. Heterozygotes develop progressive high-frequency-first hearing loss and bundle abnormalities; homozygotes are profoundly impaired. This line supports editing and pharmacological proof-of-concept studies, with species and C57BL/6N background limitations.
  modeled_mechanisms:
  - target: Stereociliary Bundle Dysfunction
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: Some heterozygous OHC bundles adopt a U shape. The human variant is matched, but human stereociliary anatomy was not measured, so anatomical fidelity remains uncertain.
    limitations: Bundle scoring was qualitative. The C57BL/6N background carries its own age-related hearing-loss allele; a background effect on the +14C>A bundle phenotype was not tested. The separate +13G>A heterozygote retained normal thresholds on both inbred and mixed backgrounds.
    readouts:
    - name: Outer hair cell stereociliary bundle shape
      target: Stereociliary Bundle Dysfunction
      direction: ALTERED
      interpretation: Bundles adopt a U shape instead of the mature V.
      evidence:
      - reference: PMID:39434156
        reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: In Mir96+14C>A heterozygotes, which have mild hearing loss by P28, some OHC stereocilia bundles have a U-shape, instead of the typical V-shape observed in wildtypes
        explanation: The morphological readout and the age at which it is present.
        quote_role: PRIMARY_RESULT
        directness: DIRECT
    evidence:
    - reference: PMID:39434156
      reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In Mir96+14C>A heterozygotes, which have mild hearing loss by P28, some OHC stereocilia bundles have a U-shape, instead of the typical V-shape observed in wildtypes
      explanation: The same lesion reproduced by a knock-in of an actual human DFNA50 allele rather than the ENU allele.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  - target: Progressive Sensorineural Hearing Loss
    relationship: RECAPITULATES
    fidelity: HIGH
    description: Heterozygotes lose hearing progressively from four weeks, starting at high frequencies and spreading, which is the same shape of course as the human disease.
    limitations: The mouse course runs over weeks and the human course over years to decades. Profound homozygous impairment from four weeks does not model the heterozygous genotypes in the founding human families.
    readouts:
    - name: ABR and DPOAE thresholds across frequency and age
      target: Progressive Sensorineural Hearing Loss
      direction: INCREASED
      interpretation: Thresholds rise - worse hearing - beginning at 32 kHz at four weeks and extending to other frequencies by 8 and 12 weeks.
      evidence:
      - reference: PMID:38985856
        reference_title: Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: These results showed that Mir9614C>A/+ mice exhibit hearing loss starting at 4 weeks at the high frequency of 32 kHz, which becomes progressive with further elevation of ABR/DPOAE thresholds at 8 and 12 weeks across other frequencies.
        explanation: The progressive, high-frequency-first threshold elevation.
        quote_role: PRIMARY_RESULT
        directness: DIRECT
    evidence:
    - reference: PMID:39434156
      reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Mir96+14C>A heterozygous mice have mild progressive hearing loss most pronounced at high frequencies and progressing with age to lower frequencies
      explanation: Direct positive result supports the model-endpoint relation.
      directness: DIRECT
      quote_role: PRIMARY_RESULT
  - target: Progressive Sensorineural Hearing Loss
    relationship: RESCUES
    fidelity: MODERATE
    description: Two independent preclinical rescue arms have been run in this line. AAV delivery of SaCas9-KKH with a guide RNA against the mutant allele into the cochleae of presymptomatic and symptomatic adult mice improved hearing long term, with better results from earlier injection. Separately, amitriptyline - selected by matching the mutant transcriptome against anti-correlated drug expression profiles - delayed progression at high frequencies.
    limitations: Both interventions remain preclinical. Editing disrupts the mutant allele, preserves surviving cells and is ineffective when delivered at sixteen weeks. Low standard-dose vector integration and assay-limited off-target results do not establish human safety. Amitriptyline exposure began with breeding parents and continued in offspring, delayed progression only temporarily, did not improve homozygotes and showed no additional benefit at double dose; the authors did not recommend it for human treatment.
    readouts:
    - name: Hearing preservation after adult cochlear AAV-SaCas9-KKH editing
      target: Progressive Sensorineural Hearing Loss
      direction: DECREASED
      interpretation: ABR and DPOAE thresholds were lower than untreated contralateral ears after early treatment, representing partial hearing preservation rather than normalization.
      evidence:
      - reference: PMID:38985856
        reference_title: Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: AAV delivery of the KKH variant of Staphylococcus aureus Cas9 (SaCas9-KKH) and sgRNA to the cochleae of presymptomatic (3-week-old) and symptomatic (6-week-old) adult Mir9614C>A/+ mutant mice improved hearing long term, with efficacy increased by injection at a younger age.
        explanation: The rescue result and its dependence on timing.
        quote_role: PRIMARY_RESULT
        directness: DIRECT
    - name: High-frequency threshold progression under oral amitriptyline
      target: Progressive Sensorineural Hearing Loss
      direction: ALTERED
      interpretation: Progression is delayed rather than halted or reversed, which is why the direction is ALTERED and not RESTORED.
      evidence:
      - reference: PMID:39434156
        reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: We chose amitriptyline to test and found that it delays the progression of hearing impairment in Mir96+14C>A heterozygotes
        explanation: The pharmacological result, stated as a delay.
        quote_role: PRIMARY_RESULT
        directness: DIRECT
    evidence:
    - reference: PMID:39434156
      reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: This is a proof of concept rather than a suggestion that amitriptyline be used as a treatment for humans carrying the MIR96+14C>A mutation, for several reasons.
      explanation: The authors' own statement of how far the rescue claim reaches. Recorded on the link so the RESCUES relationship cannot be read as a therapy claim.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
- name: Mir96 +13G>A human-allele knock-in mouse
  species: Mouse
  genotype: Mir96 tm2.1Wtsi (Mir96 +13G>A knock-in), heterozygous and homozygous
  background: C57BL/6N, and a 50 percent C3HeB/FeJ mixed background
  publication: PMID:39434156
  genes:
  - preferred_term: MIR96
    term:
      id: hgnc:31648
      label: MIR96
  description: The +13G>A human-seed knock-in has normal heterozygous ABR thresholds to one year on C57BL/6N despite subtle OHC bundle defects. A mixed-background cohort remained without a threshold phenotype to six months. Homozygotes have profound impairment and reduced IHC synaptic puncta, illustrating the limits of transferring homozygous mouse findings to human heterozygotes.
  modeled_mechanisms:
  - target: Progressive Sensorineural Hearing Loss
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: 'Heterozygotes fail to reproduce the human hearing-threshold phenotype: ABR thresholds remain normal to one year on the tested inbred background and to six months on the mixed background. The tested noise exposure did not uncover a genotype-dependent threshold difference; subtle bundle abnormalities nevertheless occur.'
    limitations: The heterozygote fails to reproduce the human threshold phenotype, but remains informative about species- and target-dependent effects. Subtle bundle pathology coexists with normal thresholds. Homozygous synaptic findings do not establish a synaptic lesion in human carriers.
    readouts:
    - name: ABR threshold in heterozygotes to one year
      target: Progressive Sensorineural Hearing Loss
      direction: UNCHANGED
      interpretation: 'A real negative result: thresholds do not differ from wild type, so the model carries a human dominant allele without the human dominant phenotype.'
      evidence:
      - reference: PMID:39434156
        reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: while Mir96+13G>A heterozygotes have normal ABR thresholds
        explanation: The negative readout itself.
        quote_role: PRIMARY_RESULT
        directness: DIRECT
    evidence:
    - reference: PMID:39434156
      reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: While the Mir96+14C>A heterozygotes mimic the phenotype observed in the family with the equivalent mutation, the Mir96+13G>A heterozygotes escape deafness while the same mutation causes progressive hearing loss in humans
      explanation: The authors stating the human-model mismatch directly, which is the substantive negative claim this link records.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  - target: Inner Hair Cell Synaptic Dysfunction
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: Homozygotes have fewer colocalized IHC synaptic puncta at four weeks; this measured synaptic phenotype differs from the +14C>A comparison.
    limitations: Only the homozygote shows the synaptic deficit, so the finding does not describe the genotype human patients carry. Because the two knock-in lines diverge this much, a programme change measured in this line cannot be assumed to hold for +14C>A or for the diminuendo allele.
    readouts:
    - name: Colocalised pre- and postsynaptic densities per inner hair cell
      target: Inner Hair Cell Synaptic Dysfunction
      direction: DECREASED
      interpretation: Fewer intact ribbon synapses per inner hair cell in homozygotes.
      evidence:
      - reference: PMID:39434156
        reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: In Mir96+13G>A homozygotes, we found significantly fewer colocalised pre- and postsynaptic densities per IHC, indicating synaptic defects
        explanation: The synaptic readout and its direction.
        quote_role: PRIMARY_RESULT
        directness: DIRECT
    evidence:
    - reference: PMID:39434156
      reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Investigations of the structural phenotype showed that one mutation appears to lead to synaptic defects, while the other has a much more severe effect on the hair cell stereociliary bundles.
      explanation: Establishes that this line is informative for a different arm of the programme than its sibling, which is what PARTIALLY_RECAPITULATES records.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
- name: Mir183/96 double-knockout mouse
  species: Mouse
  genotype: Mir183/96 null (Mir183 and Mir96 deleted together), heterozygous and homozygous
  publication: PMID:33318051
  genes:
  - preferred_term: MIR96
    term:
      id: hgnc:31648
      label: MIR96
  - preferred_term: MIR183
    term:
      id: hgnc:31554
      label: MIR183
  description: Deletion of Mir183 and Mir96 provides a loss-of-function comparator. Heterozygous hearing thresholds resemble wild type through six months; homozygotes have profound hearing loss, bundle abnormalities and reduced IHC synapses. Comparing this model with seed mutants supports an acquired-target contribution, with co-deletion, strain and expression-platform confounding.
  modeled_mechanisms:
  - target: Repression of Novel Targets Acquired by the Mutant Seed
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: The deleted allele cannot produce a mutant seed RNA. Normal heterozygous hearing argues against simple dosage insufficiency in this model but does not resolve the mechanism of every human precursor allele.
    limitations: The deletion removes Mir183 as well as Mir96, so a comparison against a seed mutant confounds the two microRNAs; and the transcriptomes were compared across studies rather than in one experiment. The conclusion is an inference from a phenotype and transcriptome contrast, not a direct demonstration that any particular acquired target drives the disease.
    readouts:
    - name: Hearing in null heterozygotes
      target: Repression of Novel Targets Acquired by the Mutant Seed
      direction: UNCHANGED
      interpretation: Normal heterozygous thresholds support a mechanism beyond reduced dosage for dominant seed alleles; they do not prove that partial loss of normal targeting is irrelevant.
      evidence:
      - reference: PMID:33318051
        reference_title: Hearing impairment due to Mir183/96/182 mutations suggests both loss and gain of function effects.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: We found that Mir183/96 heterozygous mice had normal hearing and homozygotes were completely deaf with abnormal hair cell stereocilia bundles and reduced numbers of inner hair cell synapses at four weeks old.
        explanation: The negative heterozygous result together with the homozygous phenotype.
        quote_role: PRIMARY_RESULT
        directness: DIRECT
    evidence:
    - reference: PMID:33318051
      reference_title: Hearing impairment due to Mir183/96/182 mutations suggests both loss and gain of function effects.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We propose three mechanisms of action of mutant miRNAs; loss of targets that are normally completely repressed, loss of targets whose transcription is normally buffered by the miRNA, and gain of novel targets.
      explanation: The framework this model was built to test, and the reason a failure to recapitulate here is informative rather than a dead end.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  background: C57BL/6N
- name: Constitutive and Adult-Inducible Mir96 Knockout Mice
  species: Mouse
  genotype: Mir96 null or UBC CreERT2/+; Mir96 fl/fl
  background: C57BL/6J
  publication: PMID:40641557
  genes:
  - preferred_term: MIR96
    term:
      id: hgnc:31648
      label: MIR96
  description: Single-gene loss-of-function comparators. Constitutive heterozygotes retained normal hearing through three months, whereas homozygotes progressively lost hearing. Adult biallelic inducible deletion caused hearing loss four weeks after tamoxifen at five months, without detectable cell loss at that time. HC-specific, but not SGN-specific, conditional deletion reproduced the early hearing defect. Neonatal AAV8-miR-96 delivery partially rescued null mice; sustained benefit remained in only a subset, and this was not a test of rescue of a dominant seed variant.
  modeled_mechanisms:
  - target: Impaired Adult Hair Cell Maintenance
    relationship: PERTURBS
    fidelity: MODERATE
    description: Adult deletion tests the maintenance requirement separately from congenital maturation effects.
    limitations: Deletion lacks a mutant target repertoire; the adult inducible driver is systemic, and transcriptomes use mixed whole-cochlear tissue. These experiments do not model dominant human alleles.
    readouts:
    - name: ABR thresholds after adult Mir96 deletion
      target: Impaired Adult Hair Cell Maintenance
      direction: INCREASED
      interpretation: Hearing thresholds rise after adult depletion, before detectable hair-cell or SGN loss.
      evidence:
      - reference: PMID:40641557
        reference_title: Therapeutic restoration of miR-96 prevents hearing loss in mice through modulation of noise-induced and genetic pathways.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Hearing loss in the inducible miR-96 knockout mice is likely due to impaired HC function, as HC and SGN numbers were unchanged
        explanation: Adult induced deletion separates loss of function from earlier developmental arrest and cell loss.
        directness: DIRECT
        quote_role: PRIMARY_RESULT
    evidence:
    - reference: PMID:40641557
      reference_title: Therapeutic restoration of miR-96 prevents hearing loss in mice through modulation of noise-induced and genetic pathways.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: significant hearing loss was observed at 4 weeks after last injection
      explanation: The adult-inducible deletion demonstrates a post-developmental requirement.
      directness: DIRECT
      quote_role: PRIMARY_RESULT
    - reference: PMID:40641557
      reference_title: Therapeutic restoration of miR-96 prevents hearing loss in mice through modulation of noise-induced and genetic pathways.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: the restorative effects were maintained in 50% and 38% of AAV8-miR-96-treated miR-96−/− mice at 2 and 3 months of age, respectively
      explanation: Bounds the durability and genotype of the separate null-rescue experiment.
      directness: DIRECT
      quote_role: PRIMARY_RESULT
datasets:
- accession: geo:GSE255796
  title: A Cell Type-Specific Approach to Elucidate the Role of miR-96 in Inner Ear Hair Cells
  data_type: BULK_RNA_SEQ
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  publication: PMID:38826689
  genes:
  - preferred_term: MIR96
    term:
      id: hgnc:31648
      label: MIR96
  notes: P1 bulk RNA-seq of FACS-isolated hair cells from cochlear and vestibular organs combined, with three mice per genotype (wild type, heterozygous and homozygous diminuendo). This supports cell-type enrichment, not cochlear-only or single-cell resolution. The publication reports a broad maturation-gene signature; an allele-specific Clic5 conclusion would require inspection of the gene-level data.
  evidence:
  - reference: PMID:38826689
    reference_title: A cell type-specific approach to elucidate the role of miR-96 in inner ear hair cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: An important limitation of this study is the inclusion of both cochlear and vestibular HCs to generate the RNA for bulk sequencing.
    explanation: Defines the sampled cell population.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- accession: geo:GSE247473
  title: Therapeutic Restoration of miR-96 Prevents Hearing Loss in Mice through Modulation of Noise-Induced and Genetic Pathways
  data_type: BULK_RNA_SEQ
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  publication: PMID:40641557
  genes:
  - preferred_term: MIR96
    term:
      id: hgnc:31648
      label: MIR96
  notes: Whole-cochlea transcriptomes from P28 constitutive Mir96 knockout versus wild-type mice (four per group), and adult inducible knockout versus control mice four weeks after tamoxifen (four knockout and three control samples). The paper also reports AAV rescue experiments, but those interventions are not the RNA-seq comparisons described here. Loss-of-function comparators do not reproduce the acquired target set of dominant seed variants.
  evidence:
  - reference: PMID:40641557
    reference_title: Therapeutic restoration of miR-96 prevents hearing loss in mice through modulation of noise-induced and genetic pathways.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The RNA-seq raw data as well as gene read counts for individual sample are accessible at Gene Expression Omnibus under accession number GSE247473.
    explanation: Verifies the accession-publication link; methods define the two knockout comparisons.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
references:
- reference: PMID:20301607
  title: Genetic Hearing Loss Overview.
  tags:
  - GeneReviews
discussions:
- discussion_id: mir96_clic5_direction
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Loss of Repression of Normal miR-96 Targets
  prompt: Does altered CLIC5 regulation contribute to human seed-variant DFNA50, and does its direction match the loss-of-function models?
  rationale: HEI-OC1 mimic/reporter assays support direct miR-96/miR-182 repression of CLIC5. Whole-cluster knockout raises Clic5 in P1 cochlea, and the 2025 single-Mir96-knockout study reports Clic5 among upregulated genes in P28 whole cochlea. Neither observation establishes a causal CLIC5 pathway in human seed-variant disease. The expected effect of losing normal repression is increased CLIC5, distinct from biallelic CLIC5 loss in DFNB103, but acquired targets and tissue composition can alter the net result. GSE255796 provides sorted mixed cochlear/vestibular hair-cell data for further analysis; its main text does not give a Clic5-specific result. No new gene-level analysis was performed in this review.
  evidence:
  - reference: PMID:22889583
    reference_title: MiR-183 family regulates chloride intracellular channel 5 expression in inner ear hair cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: miR-96 and miR-182 were found to be specifically overexpressed in HEI-OC1 cells into which mimics of these molecules had been transfected by liposomes causing the downregulation of CLIC5 at both the mRNA and protein levels
    explanation: Direct cell-line evidence establishes repression; it does not determine CLIC5 abundance in human mutant hair cells.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:30575790
    reference_title: The microRNA-183/96/182 Cluster is Essential for Stereociliary Bundle Formation and Function of Cochlear Sensory Hair Cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Several predicted target genes of the miR-183/96/182 cluster that are known to play important roles in HC development and function, including Clic5, Rdx, Ezr, Rac1, Myo1c, Pvrl3 and Sox2, are upregulated in the cochlea.
    explanation: The same direction confirmed in vivo, in a cluster-null cochlea.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:38826689
    reference_title: A cell type-specific approach to elucidate the role of miR-96 in inner ear hair cells.
    supports: NO_EVIDENCE
    evidence_source: MODEL_ORGANISM
    snippet: This Mir96Dmdo HC-specific RNA-seq data set is currently the only data set available for evaluating the regulatory cascade of Mir96Dmdo specifically in HCs.
    explanation: Identifies the dataset that could settle the question. Graded NO_EVIDENCE because the paper states the resource exists without reporting CLIC5 in it - it neither supports nor refutes the claim.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:40641557
    reference_title: Therapeutic restoration of miR-96 prevents hearing loss in mice through modulation of noise-induced and genetic pathways.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 11 upregulated (Ceacam16, Cldn9, Clic5, Col9a1, Col9a2, Fgfr3, Marveld2, Myh14, P2rx2, Pex26, and Slc26a4)
    explanation: The single-Mir96-knockout study reports Clic5 upregulation in P28 whole cochlea; this is not a dominant-seed or purified-hair-cell result.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- discussion_id: mir96_13ga_human_model_mismatch
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Progressive Sensorineural Hearing Loss
  prompt: Why does a mouse carrying the human MIR96 +13G>A allele in heterozygosis hear normally for a year, when the same heterozygous allele causes progressive hearing loss in the Spanish family it was taken from?
  rationale: The human +14C>A and +13G>A alleles produce distinct mouse phenotypes and transcriptomes. +13G>A heterozygotes retained normal thresholds through one year, while the corresponding human allele segregated with progressive hearing loss. The authors proposed species-specific acquired targets, including predicted +13G>A sites in human RAB11A that are absent from mouse Rab11a. This candidate has not been validated as the cause of the mismatch. Neither identical seed sequence nor a human-matched substitution guarantees conserved target repertoires. The discrepancy constrains transfer of mechanism and therapy between alleles.
  evidence:
  - reference: PMID:39434156
    reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: While the Mir96+14C>A heterozygotes mimic the phenotype observed in the family with the equivalent mutation, the Mir96+13G>A heterozygotes escape deafness while the same mutation causes progressive hearing loss in humans
    explanation: The mismatch stated by the authors of the models.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:39434156
    reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the heterozygous phenotypes differ markedly, with only one mutation resulting in hearing impairment in heterozygosis
    explanation: The divergence between the two human-allele lines, summarised.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
- discussion_id: dfna50_preclinical_translation
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - treatments#Experimental AAV2 Mutant-Allele Editing
  - treatments#Experimental Amitriptyline
  prompt: Can allele-specific editing or transcriptome-guided drugs provide durable clinical benefit in DFNA50?
  rationale: The studies establish mouse proof of concept, not human efficacy. Editing benefit depends on the treatment window and surviving cells; safety is bounded by the assays and doses used. The amitriptyline effect was temporary at high experimental exposure. The multiplex guide construct targeted +13G>A, +14C>A and the mouse-derived +15A>T sequence in engineered cells; it did not demonstrate rescue of all human MIR96 alleles and did not include the Italian +57T>C allele. General hearing and communication care remains appropriate while these approaches are investigated.
  evidence:
  - reference: PMID:39434156
    reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: This is a proof of concept rather than a suggestion that amitriptyline be used as a treatment for humans carrying the MIR96+14C>A mutation, for several reasons.
    explanation: Explicitly limits the result to preclinical proof of concept.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:38985856
    reference_title: Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: For the applications in humans, the system has to be further evaluated, including the testing in nonhuman primates and human inner ear specimen.
    explanation: The editing authors identify the translational work still needed.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
external_assertions:
- name: OMIM deafness, autosomal dominant 50 record
  source: OMIM
  assertion_type: disease_record
  external_id: OMIM:613074
  url: https://omim.org/entry/613074
  description: The OMIM phenotype record for DFNA50, and the identifier the clinical literature uses for the disorder. Recorded here rather than under mappings because the DiseaseMappings class carries only ICD-10-CM, ICD-11, MONDO and NCIT slots.
- name: ClinGen MIR96 dominant hearing-loss validity
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_01d1a7f4-8421-4be3-8fe7-2c2025f03ac9-2023-09-26T160000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_01d1a7f4-8421-4be3-8fe7-2c2025f03ac9-2023-09-26T160000.000Z
  description: Moderate gene-disease validity for autosomal dominant nonsyndromic genetic hearing loss, September 2023. The detailed table separates three included human alleles from unscored candidates with possible alternative genetic explanations.
notes: On 2026-09-23, ClinicalTrials.gov searches returned no DFNA50 studies and one MIR96 hit, NCT02101437, an unrelated platelet/antiplatelet study. These bounded searches did not identify a DFNA50-directed clinical trial. Full-text clinical and experimental sources informed this review; the original Spanish report and the CLIC5 study remained abstract-only except for accessible Spanish figure captions. Model-derived anatomy and target networks are distinguished from human observations.
mechanistic_hypotheses:
- hypothesis_group_id: mir96_allele_specific_cochlear_dysfunction
  description: Altered miRNA targeting perturbs hair-cell maturation and maintenance, bundle function, synaptic function and survival. These routes are supported primarily in mice and vary by allele, zygosity and developmental stage. Their relative contributions in human carriers remain provisional.
treatments:
- name: Hearing Aids and Communication Support
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: hearing aid amplification
  description: Offer hearing aids tailored to audiometric needs and communication support aligned with individual preferences, including sign language where desired. This is general genetic hearing-loss care; DFNA50-specific outcome estimates were not established in the reviewed family reports.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Habilitation for hearing loss includes improved access to sound through hearing aids or cochlear implants and, when desired, exposure to and teaching of American Sign Language.
    explanation: General management guidance, not an allele-specific treatment trial.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Cochlear Implantation
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  description: Consider cochlear implant assessment when hearing and aided speech understanding warrant it. Selection and counseling are individualized; the reviewed sources do not establish a DFNA50-specific implant prognosis.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Habilitation for hearing loss includes improved access to sound through hearing aids or cochlear implants and, when desired, exposure to and teaching of American Sign Language.
    explanation: Supports cochlear implantation as a general hearing-loss management option.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Genetic Counselling and Audiologic Surveillance
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  description: Explain the 50% chance of transmitting a causal heterozygous allele, variable onset/severity and uncertain age-specific penetrance. Offer appropriate family testing and serial audiologic evaluation, including in initially normal-hearing carriers.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic variant to each child.
    explanation: Transmission probability is not a penetrance estimate.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Regular follow up is recommended for all individuals with genetic hearing loss
    explanation: General surveillance guidance, tailored to the individual course.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Hearing Conservation
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: noise exposure avoidance and hearing protection
  description: Avoid repeated excessive noise exposure as part of general hearing conservation. The reviewed studies do not establish heightened noise vulnerability for every MIR96 allele or a disease-specific safe exposure threshold.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews&reg; - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: persons with documented hearing loss should be counseled appropriately and repeated overexposure to loud noises should be avoided.
    explanation: General hearing-conservation advice, without evidence of an allele-specific noise threshold.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Experimental AAV2 Mutant-Allele Editing
  therapeutic_modality: GENE_EDITING
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  context: Preclinical Mir96 +14C>A heterozygous mouse experiments
  description: AAV2 delivered SaCas9-KKH and an allele-specific sgRNA through the round window with canal fenestration, disrupting the mutant allele by end joining. Treatment at three or six weeks preserved hearing and hair cells; intervention at sixteen weeks did not improve thresholds. This is not correction of the nucleotide or an established human treatment. Editing and safety were assessed in selected mouse assays; low integration was detected at the standard dose and was below assay background at a lower dose.
  delivery_system:
    delivery_platform: VIRAL_VECTOR
    description: Local cochlear AAV2 delivery of SaCas9-KKH and sgRNA-4.
    target_cell_types:
    - preferred_term: cochlear inner hair cell
      term:
        id: CL:0000589
        label: cochlear inner hair cell
    - preferred_term: cochlear outer hair cell
      term:
        id: CL:0000601
        label: cochlear outer hair cell
  target_mechanisms:
  - target: Repression of Novel Targets Acquired by the Mutant Seed
    treatment_effect: INHIBITS
    description: Allele-specific disruption reduces the mutant product; hearing rescue supports the strategy in +14C>A mice without establishing normalization of every target transcript.
  evidence:
  - reference: PMID:38985856
    reference_title: Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: we performed editing by nonhomologous DNA end joining (NHEJ) to target a dominant Mir96 mutation
    explanation: Defines allele disruption rather than precise repair.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:38985856
    reference_title: Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In mice injected at 16 weeks of age, no difference in ABR and DPOAE thresholds was detected
    explanation: The late-intervention negative result bounds the treatment window.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:38985856
    reference_title: Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: there were 102 integration reads, making up 0.26% of the total reads
    explanation: The full-text integration result prevents an unqualified claim of no integration from the abstract.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- name: Experimental Amitriptyline
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: amitriptyline
      term:
        id: CHEBI:2666
        label: amitriptyline
  context: Preclinical Mir96 +14C>A mouse study
  description: Transcriptome-guided selection led to amitriptyline testing in drinking water, beginning with treated breeding parents and continuing in offspring. High-frequency threshold deterioration was temporarily delayed in heterozygotes. Homozygotes did not improve and doubling the dose did not add benefit. The exposure exceeded usual human dosing by body weight, and the authors explicitly did not propose clinical use for DFNA50. The responsible molecular target remains unresolved.
  evidence:
  - reference: PMID:39434156
    reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: No improvement was seen in the homozygotes drinking amitriptyline
    explanation: Preserves the genotype-specific and dose-response limitations.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:39434156
    reference_title: Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human MIR96 mutations.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: This is a proof of concept rather than a suggestion that amitriptyline be used as a treatment for humans carrying the MIR96+14C>A mutation, for several reasons.
    explanation: Explicitly limits the result to preclinical proof of concept.
    directness: DIRECT
    quote_role: PRIMARY_RESULT

📚

References & Deep Research

References

1

PMID:20301607

Genetic Hearing Loss Overview.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Autosomal Dominant Nonsyndromic Hearing Loss 50 (DFNA50, MIR96) · 2026-09-02T01:42:34Z · View source

De-novo curation of DFNA50 (MONDO:0013114, MIR96), claim issue #10461. Scope decision: DISEASE. One gene, one conserved pathograph (MIR96 point mutation -> altered target repertoire -> arrested hair cell maturation -> progressive SNHL), no member diseases to unite, and the only MONDO parent (MONDO:0019587) is an ontology grouping of unrelated DFNA loci. Stub deleted. miRNA-specific modelling decisions: - GeneDescriptor for MIR96 (hgnc:31648) uses the same shape as a protein-coding gene; the GeneTerm enum has no reachable_from constraint, so an "RNA, micro" locus type validates normally. Confirmed by validate-terms. - functional_impact_category is left ABSENT on the seed-mutation GeneticContext, with a notes block giving the reason. FunctionalImpactEnum is single-valued and the seed substitution is simultaneously hypomorphic (for the wild-type target set) and neomorphic (for transcripts complementary to the mutant seed). LOSS_OF_FUNCTION is refuted by Mir183/96 null heterozygotes hearing normally (PMID:39434156); NEOMORPHIC records only half. The Italian precursor allele DOES get a controlled value, PARTIAL_LOSS_OF_FUNCTION, because that defect is purely quantitative - the two allele classes are curated as separate pathophysiology nodes for this reason. - modifier is left ABSENT on the GO:0035195 descriptor of the "Repression of Novel Targets Acquired by the Mutant Seed" node, with a notes block. What changed is silencing specificity, not level; INCREASED/DECREASED are the PATO-bound quantitative pair, GAIN_OF_FUNCTION is defined here as activation of the same process outside regulatory constraints, and DYSREGULATED still reads as a level claim. The sibling node ("Loss of Repression of Normal miR-96 Targets") does carry modifier: DECREASED, which is honest for that target set. miR-96 / CLIC5 cross-entry link (Autosomal_Recessive_Nonsyndromic_Hearing_Loss_103): recorded, but NOT as "DFNA50 acts through CLIC5". Established: miR-96 represses CLIC5 via a conserved 3'-UTR site at nt 760-766 (PMID:22889583), and Clic5 is upregulated in the cochlea of miR-183/96/182 cluster-null mice (PMID:30575790). That direction is the opposite of DFNB103, which is a CLIC5 loss disease, so the naive convergence claim does not follow. Curated as a notes block on the loss-of-repression node plus a discussions KNOWLEDGE_GAP (mir96_clic5_direction) naming GSE255796 as the dataset that could settle whether CLIC5 moves at all in a seed mutant. Four mouse lines in animal_models with modeled_mechanisms: diminuendo (ENU seed), Mir96+14C>A and Mir96+13G>A human-allele knock-ins, and the Mir183/96 double knockout. Two FAILS_TO_RECAPITULATE links, each with limitations and evidence: the +13G>A heterozygote does not reproduce the human dominant phenotype, and the null cannot reproduce novel targeting. A HUMAN_MODEL_MISMATCH discussion records the +13G>A discrepancy. RESCUES link on the +14C>A line carries both the AAV-SaCas9-KKH editing and the amitriptyline arms, with the authors' own proof-of-concept caveat quoted so the link cannot read as a therapy claim. ABR/DPOAE threshold readouts use direction INCREASED for the mutants (a higher threshold is worse hearing) and RESTORED for the editing rescue. Deliberately not curated: no treatments block (reasoning in the dfna50_no_disease_modifying_therapy discussion - gene editing and amitriptyline are preclinical and live on the model link; importing generic SNHL management would attach another disease's evidence). No biochemical, histopathology, imaging or clinical_trials content - none published for these three families. Audiometric natural history per allele, the Italian family's vertigo, and its age-dependent penetrance are in the Solda 2012 full text, which is not retrievable (PubMed and Europe PMC both abstract-only; DOI:10.1093/hmg/ddr493 fetch returns content_type unavailable), so the numbers were not taken second-hand. Deep research: falcon, one report. preflight-dr against MONDO:0013114 PASSED - MIR96 mentioned 52 times, no competing gene (next highest was the acronym ABR at 5). The report proposed three HPO terms that do not mean what it said: HP:0008527 offered as "Postlingual sensorineural hearing impairment" (it is Congenital sensorineural hearing impairment), HP:0008607 as "Abnormality of the auditory threshold" (it is Progressive conductive hearing impairment), and HP:0000404 which does not resolve. Every term used here was resolved through OLS first. The report's clinical detail on the Italian family was not used because its underlying source is not quotable from the cache. Validation, all exit 0: validate, validate-terms, count-verified-snippets (70/70), validate-disorders, check-entity-refs, check-duplicate-keys, check-causal-targets, check-snippet-length, check-title-snippets, check-snippet-grading, check-environmental-evidence, check-folded-hyphens, verify-datasets (2/2 OK).

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 49 citations 2026-09-01T18:25:59.312481

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Autosomal dominant nonsyndromic hearing loss 50 (DFNA50), caused by MIR96 seed-region point mutations
MONDO ID: MONDO:0013114 (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Autosomal dominant nonsyndromic hearing loss 50 (DFNA50), caused by MIR96 seed-region point mutations covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

DFNA50 due to MIR96 mutation: disease-characteristics research report

Executive summary

Autosomal dominant nonsyndromic hearing loss 50 (DFNA50) is an ultra-rare, usually postlingual and progressive cochlear sensorineural hearing loss caused by heterozygous pathogenic variants in MIR96, a non-protein-coding microRNA gene at 7q32. The defining human alleles are seed-region substitutions historically designated +13G>A and +14C>A; a third established allele, NR_029512.1:c.57T>C, lies outside mature miR-96 and disrupts precursor processing. Seed mutations change both loss of normal target repression and gain of novel targets, explaining why their dominant phenotype can be more severe than heterozygous deletion. Evidence comes from a few pedigrees, cultured-cell assays, and several mouse models rather than population cohorts or EHR-scale studies. Open Targets links MIR96 (ENSG00000199158) to autosomal dominant nonsyndromic hearing loss using five evidence records, including PMIDs 19363479, 19363478, 20301607, and 24148127. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 50-MIR96)

The most important recent developments are: (1) 2024 hair-cell-specific transcriptomics identifying 215 upregulated and 428 downregulated genes in homozygous diminuendo hair cells; (2) human-variant knock-in mice demonstrating mutation-specific stereociliary versus synaptic pathology and 328 versus 693 differentially expressed genes; (3) temporary pharmacologic delay of high-frequency loss with amitriptyline in mice; and (4) long-term auditory preservation/improvement after adult cochlear AAV–SaCas9-KKH editing of the 14C>A allele. These remain preclinical; no approved disease-modifying therapy or DFNA50-specific clinical trial was identified. (zhu2024targetedgenomeediting pages 1-3, lewis2024pathologicalmechanismsand pages 17-18, lewis2024pathologicalmechanismsand pages 13-16, gwilliam2024acelltype–specific pages 1-2)

Evidence domain	Source type	Key finding with exact quantitative detail	Interpretation / limitation	Citation context ID or DOI/PMID
Human genetics: original DFNA50 families	Human familial linkage/variant study	Two Spanish families with autosomal dominant progressive nonsyndromic hearing loss carried MIR96 seed-region variants +13G>A and +14C>A; both affect conserved seed nucleotides and were not found in 462 hearing controls. The +13G>A family had affected frequencies across the audiogram, whereas +14C>A caused more severe high-frequency loss. Mutant miRNA levels were reported as about 20% of wild type.	Foundational evidence for DFNA50 due to MIR96 seed mutations; quantitative clinical details in available excerpts are limited, and PMIDs were not provided in the retrieved context.	(friedman2009micrornasandepigenetic pages 8-9, lenz2011hereditaryhearingloss pages 5-6)
Human genetics: Italian family, precursor variant discovery	Human case-control + family segregation + in vitro functional assay	Screening of 882 NSHL patients and 836/839 normal-hearing Italian controls identified MIR96 c.57T>C (reported as miR-96(+57T>C); NR_029512.1:c.57T>C; NT_007933.15:g.67447397A>G) in one autosomal dominant family. Reported onset was about 25–40 years with slow progression; the proband progressed from mild hearing loss at ~25 years to severe at 45 and profound in the sixth decade. Variant was present in 3 normal-hearing children, supporting age-dependent/incomplete penetrance.	First non-seed MIR96 DFNA50 allele; phenotype appears milder/later than seed mutations. Control denominator appears as 836 in abstract text and 839 in results text of available excerpts.	(solda2012anovelmutation pages 5-7, robusto2014inheritedhearingloss pages 91-92, solda2012anovelmutation pages 1-2, solda2012anovelmutation pages 2-4)
In vitro mechanism: precursor-processing defect	In vitro transient-expression / qRT-PCR	For the Italian +57T>C precursor variant, mature miR-96 was reduced by 85% (P=0.0006) and miR-96* by 77% (P=0.019), while precursor levels were unaffected; compensatory mutation restored expression.	Supports a quantitative pathogenic mechanism through altered hairpin structure and impaired Dicer processing, rather than altered seed specificity.	(solda2012anovelmutation pages 2-4)
Mouse model: Dmdo discovery and phenotype	Animal model (ENU mutant mouse)	The diminuendo (Dmdo) mouse carries an A>T substitution in the Mir96 seed region. Heterozygotes lost the Preyer reflex between 4–6 weeks, and compound action potential/ABR-type thresholds were raised by about 60 dB at 4 weeks; homozygotes had no cochlear responses. Microarray showed 96 transcripts significantly altered, with downregulation of Slc26a5, oncomodulin/Ocm, Gfi1, Ptprq, Pitpnm1.	Strong mechanistic model for progressive DFNA50-like hearing loss; background is mouse, not human, and transcriptomics were whole-organ rather than cell-specific.	(lewis2009anenuinducedmutation pages 1-2) DOI:10.1038/ng.369
Hair-cell-specific transcriptomics	Animal model (newborn Mir96Dmdo hair-cell RNA-seq)	First HC-specific RNA-seq dataset from newborn Mir96Dmdo mice identified 215 upregulated and 428 downregulated genes in homozygous mutant hair cells versus wild type; highlighted downregulated deafness/development genes included Myo15a, Myo7a, Ush1c, Gfi1, Ptprq.	Refines cell-autonomous consequences in hair cells; newborn time point may not capture later degenerative stages.	(gwilliam2024acelltype–specific pages 1-2) DOI:10.3389/fauot.2024.1400576
Human-mutation knock-in transcriptomics	Animal model (2024 humanized Mir96 knock-in mice)	In 2024 knock-in mice carrying human MIR96 variants, homozygous Mir96+13G>A had 328 DEGs and homozygous Mir96+14C>A had 693 DEGs by RNA-seq. Table summary reports heterozygous Mir96+14C>A with progressive hearing loss, while Mir96+13G>A heterozygotes had normal hearing in mice.	Demonstrates mutation-specific biology and supports gain-of-novel-target effects; mismatch between human and mouse heterozygous +13G>A phenotype is a limitation.	(lewis2024pathologicalmechanismsand pages 17-18, lewis2024pathologicalmechanismsand pages 16-17) DOI:10.1186/s13073-024-01394-5
Pharmacologic proof-of-concept	Animal model therapeutic experiment	Transcriptome-based drug repurposing selected amitriptyline. Mir96+14C>A mice received 200 µg/mL or 400 µg/mL in drinking water; hearing loss in heterozygotes was significantly delayed at 24–36 kHz, most visibly at 30 kHz at 4 weeks, but 400 µg/mL did not improve over 200 µg/mL and homozygotes did not improve.	Proof of concept for pharmacologic delay of progression; effect was temporary and mouse doses were higher than standard human dosing, limiting translational use.	(lewis2024pathologicalmechanismsand pages 17-18, lewis2024pathologicalmechanismsand pages 13-16) DOI:10.1186/s13073-024-01394-5
Adult genome editing	Animal model gene-editing therapy	2024 study developed AAV-delivered SaCas9-KKH with sgRNA against Mir96 14C>A and treated presymptomatic 3-week-old and symptomatic 6-week-old adult heterozygous mice. Hearing improved long term, with better efficacy at the younger age; authors also reported transient Cas9 expression and no evidence of AAV genomic integration. A dual-AAV “master” system targeted all known human MIR96 mutations.	Highly relevant preclinical therapy for dominant MIR96 disease; available excerpts did not provide exact editing percentages or ABR/DPOAE delta values.	(zhu2024targetedgenomeediting pages 1-3, zhu2024targetedgenomeediting pages 12-14) DOI:10.1126/scitranslmed.adn0689

Table: This table summarizes the strongest human, in vitro, and animal evidence for DFNA50 caused by MIR96 variants, including core family reports, mechanistic assays, transcriptomics, and 2024 therapeutic studies. It is useful as a compact citation-ready map of what is known and where current evidence remains limited.

1. Disease information

Definition and nomenclature

DFNA50 is a Mendelian form of autosomal dominant nonsyndromic sensorineural hearing loss caused by pathogenic MIR96 variants. “Nonsyndromic” means that hearing impairment is the principal phenotype, without a reproducible extra-auditory syndrome. Common names include DFNA50, deafness, autosomal dominant 50, MIR96-related hearing loss, and autosomal dominant nonsyndromic hearing loss due to MIR96 mutation.

Identifiers

OMIM phenotype: 613074, Deafness, autosomal dominant 50.
Gene: MIR96, microRNA 96; Ensembl ENSG00000199158. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 50-MIR96)
Locus: chromosome 7q32; MIR96 lies in an approximately 4.5-kb cluster with MIR183 and MIR182. (solda2012anovelmutation pages 1-2)
MONDO: the user-supplied MONDO:0013114 should be verified before production use. The retrieved Open Targets mapping is the broader MONDO:0019587, “autosomal dominant nonsyndromic hearing loss,” rather than a demonstrated DFNA50-specific MONDO record. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 50-MIR96)
Orphanet: no confidently verified DFNA50-specific Orpha number was found.
ICD-10-CM: no genotype-specific code; use phenotype codes such as H90.3 (bilateral sensorineural hearing loss) where appropriate.
ICD-11: classify under sensorineural hearing loss; no MIR96-specific code was verified.
MeSH: Hearing Loss, Sensorineural and Hearing Loss, Genetic are appropriate indexing concepts.

Evidence granularity

The phenotype is derived primarily from individual family members aggregated in pedigree publications—not from EHR cohorts, registries, or population surveillance. The original Spanish report concerned two pedigrees; the Italian study screened 882 genetically undiagnosed NSHL cases and 836 controls in its abstract (839 controls in the results text), finding one causal family. (solda2012anovelmutation pages 1-2, solda2012anovelmutation pages 2-4)

2. Etiology, risk, protection, and gene–environment interaction

Primary cause

The necessary initiating factor is a heterozygous germline pathogenic MIR96 allele. For seed substitutions, altered nucleotide complementarity changes the set of mRNAs recognized by miR-96 while also reducing mature-miRNA abundance. For c.57T>C, altered precursor structure impairs DICER processing and quantitatively reduces mature miR-96 and miR-96* without changing the mature miR-96 seed. (lenz2011hereditaryhearingloss pages 5-6, solda2012anovelmutation pages 1-2, solda2012anovelmutation pages 2-4)

Genetic risk factors

A pathogenic allele confers an approximately 50% transmission probability per pregnancy, independent of sex.
Family history is a strong risk marker, but de novo occurrence is biologically possible in dominant hearing loss.
Penetrance appears age-dependent and may be incomplete, especially for c.57T>C: three currently normal-hearing children carried the familial variant but were below the family’s average onset age. (solda2012anovelmutation pages 2-4)
No validated modifier gene, protective allele, founder effect, carrier frequency, or anticipation has been demonstrated for DFNA50.
Consanguinity is not etiologically important for this dominant disorder.

Environmental and lifestyle factors

No toxin, infection, diet, smoking pattern, or occupational exposure causes genetically defined DFNA50. Noise, ototoxic medicines, and aging may add independent cochlear injury, but a DFNA50-specific gene–environment interaction has not been quantified. Humanized +13G>A mice retained normal ABR thresholds even after noise exposure in one experiment, illustrating that interaction may be allele- and species-specific rather than established generally. (lewis2024pathologicalmechanismsand pages 16-17)

Protective factors

No genetic or pharmacologic protective factor is validated in humans. Prudent hearing conservation—avoiding excessive noise and unnecessary ototoxic exposure—is reasonable tertiary prevention but has not been shown to alter MIR96-specific natural history. Amitriptyline delayed loss temporarily in one mouse line and is not a recommended protective drug. (lewis2024pathologicalmechanismsand pages 17-18, lewis2024pathologicalmechanismsand pages 13-16)

3. Phenotypes

Core phenotype

Phenotype	Characteristics and frequency	Suggested HPO term
Sensorineural hearing impairment	Defining feature in clinically penetrant carriers; cochlear, generally bilateral	HP:0000407 Sensorineural hearing impairment; HP:0000365 Hearing impairment
Progressive hearing loss	Typical course; gradual worsening over years or decades	HP:0001730 Progressive hearing impairment
Postlingual/delayed onset	Spanish families were postlingual; c.57T>C onset approximately 25–40 years	HP:0008527 Postlingual sensorineural hearing impairment; adult-onset qualifier
High-frequency-predominant loss	Particularly prominent with +14C>A; +13G>A affected frequencies more uniformly	HP:0005101 High-frequency hearing impairment
Severe/profound hearing loss	Possible late stage; Italian proband progressed from mild at ~25, severe at 45, to profound in her sixth decade	HP:0000404 Sensorineural hearing impairment, severe; HP:0012715 Profound hearing impairment
Down-sloping audiogram	Documented in the Italian c.57T>C proband, with all tested frequencies affected	HP:0008607 Abnormality of the auditory threshold plus audiogram-shape annotation
Vertigo	Reported in the Italian proband, her mother, and affected brother; not established as a universal DFNA50 feature	HP:0002321 Vertigo

The Spanish +13G>A family had broadly similar involvement across frequencies, whereas +14C>A produced more severe high-frequency loss. Mutant miRNA abundance was approximately 20% of wild type in available evidence. (friedman2009micrornasandepigenetic pages 8-9)

The c.57T>C proband had bilateral sensorineural impairment beginning mildly at approximately 25 years, becoming severe at 45 and profound in the sixth decade. No affected family member reported visual or olfactory impairment, although vertigo occurred in three relatives. (solda2012anovelmutation pages 2-4)

Severity, progression, and frequency estimates

Reliable percentages cannot be assigned because the published denominator is only a few families and carriers. “Common,” “occasional,” and “rare” frequencies should therefore not be inferred from pedigree counts. Severity and onset are variable both between alleles and within families. The non-seed c.57T>C phenotype appears later and slower than the original seed-variant phenotypes. (solda2012anovelmutation pages 5-7, goel2024micrornaandrare pages 4-6)

Behavioral, laboratory, and quality-of-life findings

No characteristic behavioral change, serum biomarker, metabolic abnormality, or histopathologic biopsy finding is known. Hearing loss can impair communication, education, employment, safety, social participation, and quality of life; however, no DFNA50-specific EQ-5D, SF-36, PROMIS, or hearing-related QoL cohort exists. Contemporary hearing-loss literature supports these general impacts, but extrapolation to DFNA50 should be labeled. (rosa2024hearinglossgenetic pages 4-5)

4. Genetic and molecular information

Gene annotation

Symbol/name: MIR96 / microRNA 96.
Molecule: approximately 21–24-nt regulatory noncoding RNA, not a protein.
Cluster: MIR183–MIR96–MIR182, coordinately expressed in neurosensory organs.
Expression: cochlear inner and outer hair cells; experimental expression also occurs in other sensory tissues, but human disease remains predominantly auditory. (lenz2011hereditaryhearingloss pages 5-6, solda2012anovelmutation pages 1-2, gwilliam2024acelltype–specific pages 1-2)

Because MIR96 does not encode a protein, terms such as missense, nonsense, protein misfolding, catalytic deficiency, PDB structure, and dominant-negative protein are inapplicable. Variant class should be recorded as single-nucleotide variants in a microRNA seed or precursor.

Established pathogenic variants

MIR96 +13G>A: historical mature/pre-miRNA-relative nomenclature; a seed-region nucleotide substitution affecting target recognition and mature-miRNA production. It segregated in a Spanish dominant pedigree and was absent from 462 hearing controls in the original evidence summarized by later sources. (friedman2009micrornasandepigenetic pages 8-9, lenz2011hereditaryhearingloss pages 5-6)
MIR96 +14C>A: adjacent seed-region substitution; associated with particularly high-frequency-predominant progressive hearing loss. (friedman2009micrornasandepigenetic pages 8-9)
NR_029512.1:c.57T>C; historical miR-96(+57T>C); older genomic designation NT_007933.15:g.67447397A>G. It lies in the precursor stem and miR-96 sequence, enlarges a bulge near DICER cleavage, and reduces mature miR-96 by 85% (P=0.0006) and miR-96 by 77% (P=0.019) without reducing precursor levels. A compensatory mutation restoring hairpin pairing rescued expression, providing strong functional evidence. (solda2012anovelmutation pages 1-2, solda2012anovelmutation pages 2-4)

HGVS must be normalized against the current MANE/RefSeq genomic build before clinical reporting because the foundational papers use historical precursor-relative notation. These are germline variants; no somatic DFNA50 mechanism is known. Contemporary ClinVar classifications and gnomAD allele counts should be rechecked directly at ingestion time; the family studies found the variants absent from their hearing controls, but that is not equivalent to a modern global allele frequency. (solda2012anovelmutation pages 1-2, solda2012anovelmutation pages 2-4)

Functional consequence and disease mechanism class

Seed mutations combine:

loss of normal targeting, including reduced repression/buffering of wild-type targets;
gain of novel targeting, because the altered seed recognizes new 3′-UTR motifs; and
reduced mature-miRNA abundance/processing.

The dominant phenotype is therefore best considered a neomorphic gain-of-target plus partial loss-of-function mechanism, not simple haploinsufficiency. Heterozygous Mir183/96-null mice hear normally, whereas several heterozygous seed-mutant mice lose hearing. (lewis2024pathologicalmechanismsand pages 17-18, lewis2024pathologicalmechanismsand pages 16-17)

No validated modifier genes, disease-specific methylation signature, chromosomal rearrangement, copy-number disorder, or structural-variant mechanism has been reported.

5. Environmental information

There is no evidence that infection, radiation, pollution, alcohol, smoking, diet, exercise, or occupation initiates DFNA50. Environmental causes of sensorineural loss remain relevant as additive or alternative diagnoses: acoustic trauma, aminoglycosides, platinum chemotherapy, loop diuretics, congenital CMV, meningitis, and age-related hearing loss. Noise protection and medication review are sensible because cochlear hair-cell reserve is finite, but their MIR96-specific effect size is unknown.

No infectious agent, zoonotic transmission, vaccine strategy, or CHEBI-coded causal toxicant is intrinsic to DFNA50.

6. Mechanism and pathophysiology

Ordered causal chain

A heterozygous MIR96 seed-region point mutation leads to altered seed complementarity and reduced normal miR-96 maturation; alternatively, c.57T>C leads to abnormal precursor folding and impaired DICER cleavage. (solda2012anovelmutation pages 1-2, solda2012anovelmutation pages 2-4)
Altered mature miR-96 leads to loss of repression/buffering of normal mRNA targets and, for seed alleles, gain of repression of novel mRNAs. (lewis2024pathologicalmechanismsand pages 17-18)
Broad target-network dysregulation leads to incomplete establishment and maintenance of cochlear hair-cell identity; 2024 hair-cell RNA-seq supports repression of supporting-cell transcriptional programs as one normal miR-96 role. (gwilliam2024acelltype–specific pages 1-2)
Hair-cell identity/maturation failure leads to reduced expression of auditory-development and function genes—including MYO15A, MYO7A, USH1C, GFI1, PTPRQ, OCM, and SLC26A5—and to abnormal electrophysiologic maturation. (lewis2009anenuinducedmutation pages 1-2, lewis2024pathologicalmechanismsand pages 17-18, gwilliam2024acelltype–specific pages 1-2)
These molecular abnormalities lead to mutation-dependent branching pathology: stereociliary disorganization/loss and hair-bundle degeneration, or reduced inner-hair-cell ribbon synapses/disorganized innervation. (lewis2024pathologicalmechanismsand pages 16-17)
Structural and synaptic dysfunction leads to impaired mechanoelectrical transduction, outer-hair-cell amplification, and auditory-nerve activation; this relationship is demonstrated in mice and inferred for human DFNA50.
Persistent dysfunction leads to progressive hair-cell degeneration, especially in basal/high-frequency cochlear regions, resulting in bilateral progressive sensorineural hearing loss and eventually severe/profound deafness. (friedman2009micrornasandepigenetic pages 8-9, lewis2009anenuinducedmutation pages 1-2)

Molecular pathways and cellular processes

No single canonical Wnt, MAPK, mTOR, or PI3K–AKT cascade explains DFNA50. The proximal pathway is miRNA biogenesis and RISC-mediated post-transcriptional gene silencing: pri-miRNA processing by DROSHA–DGCR8, nuclear export, DICER cleavage, Argonaute/RISC loading, and seed-dependent recognition of target 3′ UTRs. A mature miRNA may regulate hundreds of transcripts through mRNA destabilization and translational inhibition. (solda2012anovelmutation pages 1-2)

Suggested GO biological-process terms include:

GO:0035195 gene silencing by miRNA
GO:0006397 mRNA processing
GO:0031054 pre-miRNA processing
GO:0030219 megakaryocyte differentiation is not relevant and should not be imported merely from broad miRNA annotations
GO:0050910 detection of mechanical stimulus involved in sensory perception of sound
GO:0042490 mechanoreceptor differentiation
GO:0035315 hair cell differentiation
GO:0048870 cell motility only if tied specifically to stereocilia/cytoskeletal data
GO:0098609 cell-cell adhesion, GO:0007015 actin filament organization, and synapse-organization terms as supported by model datasets.

Relevant GO cellular components are the RNA-induced silencing complex, cytoplasm, stereocilium, hair-cell apical surface, ribbon synapse, and postsynaptic density. Suggested terms include GO:0016442 RISC complex, GO:0032420 stereocilium, and GO:0098982 GABA-ergic synapse only for specific brainstem model work, not core human DFNA50.

Tissue damage, metabolism, and immunity

The demonstrated downstream tissue injury is hair-bundle disruption followed by sensory-hair-cell degeneration. Oxidative stress, inflammation, autophagy, immune dysregulation, fibrosis, ischemia, and a disease-specific metabolic signature have not been established as primary DFNA50 mechanisms. No human proteomic, metabolomic, lipidomic, or methylomic signature is available.

Molecular profiling and advanced technologies

Dmdo microarray: 96 significantly altered transcripts in homozygotes; downregulated genes included Slc26a5, Ocm, Gfi1, Ptprq, and Pitpnm1, while hundreds were predicted to be upregulated and novel mutant-seed targets were downregulated. Exact abstract quote: “Microarray analysis revealed 96 transcripts with significantly altered expression in homozygotes.” (lewis2009anenuinducedmutation pages 1-2)
2024 hair-cell RNA-seq: 215 upregulated and 428 downregulated genes in newborn homozygous Dmdo hair cells. The authors concluded that the data support miR-96 “possibly as a repressor of supporting cell transcriptional programs in HCs.” The dataset is publicly available at gEAR. (gwilliam2024acelltype–specific pages 1-2)
2024 human-variant knock-ins: 328 DEGs in +13G>A and 693 in +14C>A homozygotes; only 124 were initially described as shared, with detailed supplementary accounting reporting 127 significant shared genes under the stated FDR criteria. Bulk organ-of-Corti profiling dilutes hair-cell-specific effects. (lewis2024pathologicalmechanismsand pages 17-18)
No DFNA50 human single-cell, spatial-transcriptomic, organoid, proteomic, or multi-omic diagnostic study was identified.

7. Anatomical structures affected

Organ and tissue levels

The primary organ is the inner ear, specifically the cochlea and organ of Corti. Suggested anatomy terms are UBERON:0001844 inner ear, UBERON:0001851 cochlea, and the corresponding current UBERON entry for organ of Corti after ontology validation. No consistent outer- or middle-ear abnormality is expected; Dmdo mice had grossly normal middle and inner-ear architecture despite microscopic sensory pathology. (lewis2009anenuinducedmutation pages 1-2)

Cell level

Primary populations are:

cochlear inner hair cells;
cochlear outer hair cells;
possibly secondary effects on afferent synapses/spiral-ganglion innervation;
supporting cells as an aberrantly retained transcriptional identity rather than necessarily the primary injured population.

Suggested Cell Ontology terms: CL:0000202 auditory hair cell, with current child terms for inner and outer hair cells; verify exact release-specific IDs before ingestion.

Subcellular level and localization

Relevant compartments are the pre-miRNA hairpin/RISC machinery, hair-cell cytoplasm, apical stereociliary bundle, and IHC ribbon synapse. Human hearing loss is generally bilateral; asymmetry was not established as a defining feature. Basal cochlear damage provides a plausible anatomical basis for high-frequency predominance, demonstrated most clearly in mouse models. (friedman2009micrornasandepigenetic pages 8-9, lewis2009anenuinducedmutation pages 1-2)

8. Temporal development

DFNA50 is generally chronic, insidious, postlingual, and progressive. The original seed-variant families developed progressive postlingual loss; c.57T>C caused onset around 25–40 years and slow worsening over decades. (solda2012anovelmutation pages 5-7, lenz2011hereditaryhearingloss pages 5-6, solda2012anovelmutation pages 2-4)

A practical staging model is:

Presymptomatic carrier stage: normal audiogram, particularly in younger carriers.
Early stage: mild threshold elevation, often high-frequency.
Intermediate stage: progressive multiband loss with speech-in-noise difficulty and increasing amplification needs.
Advanced stage: severe-to-profound bilateral loss and possible cochlear-implant candidacy.

There is no remission pattern. The disease is lifelong once manifest. Critical intervention windows are inferred from preservation of viable hair cells: auditory rehabilitation should begin when functional difficulty emerges, and mutation-directed therapy—if translated—would probably work best before extensive degeneration. In 2024 editing experiments, treatment at three weeks outperformed treatment at six weeks in mice. (zhu2024targetedgenomeediting pages 1-3)

9. Inheritance and population

Inheritance: autosomal dominant.
Penetrance: likely high but age-dependent; incomplete penetrance remains possible for c.57T>C.
Expressivity: variable in age at onset, audiometric configuration, and progression.
Sex ratio: no established difference; males and females can be affected.
Anticipation: not reported.
Germline mosaicism: not reported, although low recurrence risk cannot be absolutely excluded after an apparently de novo event.
Founder effects/geographic distribution: variants were initially reported in Spanish families and c.57T>C in an Italian family; evidence supports private familial alleles rather than established founder mutations. Screening of 567 Spanish inherited-hearing-loss families and 150 American dominant families is discussed in the literature, with no replication variants in the latter cohort. (solda2012anovelmutation pages 2-4)
Prevalence/incidence: no reliable cases-per-100,000 or annual incidence estimate exists. DFNA50 appears exceptionally rare: one c.57T>C family was found among 882 Italian undiagnosed NSHL patients, and the two original seed mutations were absent from 462 controls. These are ascertainment studies, not prevalence estimates. (lenz2011hereditaryhearingloss pages 5-6, solda2012anovelmutation pages 1-2)
Carrier frequency: unknown; population databases should be queried variant-by-variant using current coordinates.

10. Diagnostics

Clinical evaluation

Diagnosis begins with history, a three-generation pedigree, otoscopy, and comprehensive audiology:

bilateral pure-tone air/bone audiometry;
speech reception and word recognition, including speech-in-noise when possible;
tympanometry to exclude conductive disease;
otoacoustic emissions to assess outer-hair-cell function;
auditory brainstem response when behavioral testing is unreliable;
vestibular assessment if vertigo is present.

No blood chemistry, urine assay, imaging signature, or biopsy diagnoses DFNA50. MRI/CT is reserved for atypical asymmetry, neurologic signs, implant planning, or another suspected lesion.

Molecular testing

The preferred method is a comprehensive hereditary-hearing-loss NGS panel that explicitly captures noncoding MIR96 and its precursor/seed region, with deletion/duplication analysis for other genes. Conventional exome sequencing may miss MIR96 because it is noncoding and poorly covered; WGS can detect it if properly analyzed. If a familial variant is known, targeted Sanger or NGS testing is efficient. Segregation and ACMG/AMP interpretation should incorporate rarity, phenotype, cosegregation, seed conservation, and functional processing/target data.

CMA, karyotyping, FISH, mitochondrial sequencing, and repeat-expansion testing are not first-line tests for classic DFNA50, but broader testing may be appropriate when phenotype or pedigree suggests another diagnosis. RNA-seq, proteomics, metabolomics, epigenomics, and liquid biopsy are research tools, not validated diagnostics.

Diagnostic criteria and differential diagnosis

There are no formal DFNA50-specific clinical criteria. A molecular diagnosis requires a compatible progressive sensorineural phenotype plus a pathogenic/likely pathogenic MIR96 variant, or compelling segregation and functional evidence for a novel variant.

Differentials include other dominant progressive nonsyndromic forms—KCNQ4/DFNA2, WFS1/DFNA6/14/38, TECTA/DFNA8/12, EYA4/DFNA10, MYO6/DFNA22, POU4F3/DFNA15, ACTG1/DFNA20/26—and acquired noise, ototoxic, autoimmune, infectious, or age-related loss. Syndromic disease should be reconsidered if retinal, renal, cardiac, neurologic, pigmentary, or vestibular findings exceed the limited DFNA50 phenotype.

Screening

Newborn physiologic screening may be normal because onset can be delayed. Once a familial variant is known, cascade genetic testing plus baseline audiometry and longitudinal surveillance is the most efficient secondary-prevention strategy. General reviews emphasize that delayed progressive forms can pass newborn screening and that molecular diagnosis improves prognosis, counseling, and timely intervention. (rosa2024hearinglossgenetic pages 4-5)

11. Outcome and prognosis

DFNA50 is disabling but not known to shorten life expectancy or increase disease-specific mortality. Five- and ten-year survival statistics are therefore not applicable. The principal outcome is progressive auditory disability, potentially reaching profound deafness.

No spontaneous recovery is expected. Hearing aids and cochlear implants can improve communication but do not reverse the underlying genetic lesion or regenerate lost hair cells. Prognosis depends mainly on the allele, current hearing thresholds, progression rate, speech recognition, and residual hair-cell/neural function; no validated molecular prognostic biomarker exists.

DFNA50-specific cochlear-implant outcomes have not been reported in a meaningful cohort. Because the major lesion is sensory hair-cell rather than primary spiral-ganglion degeneration, benefit is biologically plausible, but this is an inference. A 2023 genetic CI cohort found poorer outcomes particularly when mutations involved neural cochlear components, supporting—not proving—the expectation that sensory lesions may fare better. General CI evidence should not be represented as DFNA50-specific. (tropitzsch2023variabilityincochlear pages 1-5)

For context, a 2024 prospective study of 100 older adults with severe/profound loss found an 18-month HUI3 improvement of 0.13 (95% CI 0.07–0.18; P<0.001), loneliness reduction of 0.61, and Hearing Handicap Inventory improvement of 8.7 points after implantation. These values demonstrate rehabilitation potential but were not obtained from MIR96 carriers. (cuda2024improvingqualityof pages 1-2)

12. Treatment and current implementation

Current clinical care

There is no FDA/EMA-approved MIR96-specific drug or gene therapy. Management follows progressive sensorineural-hearing-loss practice:

regular audiologic monitoring, generally annually or sooner with subjective change;
appropriately fitted bilateral hearing aids for aidable loss;
communication strategies, remote microphones/assistive listening devices, captioning, and auditory rehabilitation;
speech-language and educational support for pediatric onset;
cochlear-implant evaluation when hearing aids no longer provide adequate speech understanding;
management of tinnitus or vertigo when present;
genetic counseling and cascade testing.

Suggested NCIT intervention concepts include Hearing Aid, Cochlear Implantation, Auditory Rehabilitation, Genetic Counseling, Genetic Testing, CRISPR-Cas9 Gene Editing, and Adeno-Associated Virus Vector Therapy; exact NCIT codes should be validated against the current release.

The 2024 American Cochlear Implant Alliance recommends individualized, ear-specific evaluation and a revised “60/60” referral framework rather than waiting for bilateral profound loss. This is general adult guidance, not MIR96-specific. (zeitler2024americancochlearimplant pages 1-3)

Experimental pharmacotherapy

Transcriptome anti-correlation nominated amitriptyline, a tricyclic antidepressant. In +14C>A heterozygous mice, 200 µg/mL in drinking water significantly delayed threshold deterioration at 24–36 kHz, most clearly at 30 kHz at four weeks. A 400-µg/mL dose offered no additional benefit; homozygotes did not improve. The effect was temporary, doses were far above standard human exposure by body weight, and adverse-effect liability is substantial. The authors explicitly stated that this was proof of concept, not a recommendation for human use. (lewis2024pathologicalmechanismsand pages 17-18, lewis2024pathologicalmechanismsand pages 13-16)

Genome editing—major 2024 development

Zhu et al., published July 2024 in Science Translational Medicine, optimized SaCas9-KKH plus mutation-specific sgRNA, delivered by AAV to the cochlea of heterozygous Mir96^14C>A/+ mice. Both presymptomatic three-week-old and symptomatic six-week-old adults had long-term auditory improvement/preservation, with greater efficacy at the younger age. Cas9 expression was transient, and the investigators found no evidence of AAV genomic integration. A dual-AAV “master” construct incorporated guides against all known human MIR96 mutations; mouse and human MIR96 sequences are 100% homologous. (zhu2024targetedgenomeediting pages 1-3)

Exact abstract quote: “Targeted genome editing of MIR96 mutations preserved long-term hearing in adult mice without evidence of genomic integration.” The work is strong preclinical evidence but does not establish human safety, off-target risk, immune tolerability, surgical delivery feasibility, durability over a human lifespan, or efficacy after advanced hair-cell loss. DOI: 10.1126/scitranslmed.adn0689, July 2024. (zhu2024targetedgenomeediting pages 1-3)

No DFNA50-targeted interventional trial or NCT identifier was found in the ClinicalTrials.gov search. Cell therapy, ASOs, siRNA, immunotherapy, or gene replacement are not clinically established; allele-selective silencing is mechanistically attractive because one wild-type copy is sufficient in heterozygous knockout mice. (lewis2024pathologicalmechanismsand pages 13-16, lewis2024pathologicalmechanismsand pages 16-17)

13. Prevention

Primary prevention

The mutation cannot be prevented by lifestyle change. Reproductive options after molecular diagnosis include genetic counseling, natural conception with prenatal diagnosis, preimplantation genetic testing for monogenic disease, donor gametes, or adoption. Decisions require nondirective counseling because hearing status, Deaf identity, variable expressivity, and emerging treatments affect values and preferences.

Secondary prevention

Cascade testing of adult and minor relatives when results will change surveillance or early intervention.
Baseline and serial audiograms for carriers, including those who passed newborn screening.
Early amplification and communication support when functional loss appears.
Prospective trial readiness through precise HGVS confirmation and natural-history documentation.

Tertiary prevention

Use hearing conservation, avoid unnecessary ototoxic drugs, treat middle-ear disease promptly, optimize amplification, and refer before speech recognition becomes extremely poor. No vaccine, medication prophylaxis, or public-health sanitation intervention prevents DFNA50.

14. Other species and natural disease

No naturally occurring veterinary DFNA50 syndrome, breed association, zoonotic transmission, or cross-species infectious susceptibility was identified. The relevant orthologue is Mir96 in mouse and miR-96 orthologues in zebrafish and other vertebrates. MIR96 sequence and neurosensory expression are strongly conserved.

In zebrafish, the miR-183 family is expressed in inner-ear and lateral-line hair cells. Experimental overexpression of miR-96/miR-182 can expand sensory patches and hair-cell numbers, whereas knockdown reduces hair cells and disrupts semicircular canals and neuromasts. These are induced developmental phenotypes, not naturally occurring veterinary disease. (solda2012anovelmutation pages 1-2)

Suggested taxonomy identifiers: Homo sapiens, NCBI Taxon 9606; Mus musculus, 10090; Danio rerio, 7955. No VBO breed term applies.

15. Model organisms

Diminuendo mouse

The ENU-induced Mir96^Dmdo allele is an A>T seed substitution with semidominant inheritance. Heterozygotes lose the Preyer reflex at four to six weeks and have thresholds elevated by approximately 60 dB at four weeks; homozygotes have no cochlear responses. Homozygotes develop abnormal stereocilia by postnatal days 4–5 and marked degeneration by day 7; heterozygotes later lose many outer hair cells in middle/basal turns. Vestibular hair-cell pathology and circling occur, especially in severe animals. (lewis2009anenuinducedmutation pages 1-2)

The landmark abstract states: “Heterozygotes show progressive loss of hearing and hair cell anomalies, while homozygotes have no cochlear responses.” DOI: 10.1038/ng.369, May 2009; PMID 19363478. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 50-MIR96, lewis2009anenuinducedmutation pages 1-2)

Human-variant knock-in mice

Knock-in models carry human +13G>A or +14C>A alleles. Homozygotes of both are profoundly deaf; +14C>A heterozygotes develop progressive loss from around four weeks, whereas +13G>A heterozygotes retain normal ABR thresholds up to one year despite subtle shortest-row OHC stereocilia loss. +13G>A homozygotes show reduced IHC synaptic densities, while +14C>A produces more severe stereociliary-bundle pathology. The failure of mouse +13G>A heterozygotes to reproduce human deafness is an important species/3′-UTR limitation; human RAB11A, for example, has mutant-seed matches absent from mouse Rab11a. (lewis2024pathologicalmechanismsand pages 16-17)

Null and cluster models

Heterozygous Mir183/96 double-null mice have normal hearing, whereas homozygotes are profoundly deaf with abnormal bundles and reduced IHC synapses. This comparison is central evidence that seed substitutions act through gained novel targets, not merely loss of MIR96 dosage. Cluster overexpression/misexpression also causes progressive loss and eventual inner/outer hair-cell degeneration, showing that cochlear homeostasis is sensitive to miRNA dosage in either direction. (lewis2024pathologicalmechanismsand pages 17-18, lewis2024pathologicalmechanismsand pages 16-17)

Model strengths, limitations, and uses

Strengths: conserved mature sequence, accessible cochlear physiology, ABR/DPOAE endpoints, hair-cell ultrastructure, allele-specific targeting, and direct therapeutic testing. Limitations: much faster murine course, genetic-background effects, divergent target 3′ UTRs, homozygous models more severe than human dominant disease, and uncertain translation of cochlear dosing/surgery. Models are suited to target-network analysis, hair-cell maturation, therapeutic-window definition, pharmacologic screening, allele-selective silencing, and in vivo genome editing.

Resources include MGI, IMSR/MMRRC where lines are deposited, ArrayExpress E-TABM-489 for the original Dmdo microarray, gEAR for 2024 hair-cell RNA-seq, and SRA PRJNA1088125 for the 2024 editing study. (lewis2009anenuinducedmutation pages 1-2, zhu2024targetedgenomeediting pages 14-16, gwilliam2024acelltype–specific pages 1-2)

Evidence assessment and key gaps

Human evidence strongly supports MIR96 causality through segregation, absence in controls, evolutionary conservation, and functional assays, but the clinical evidence base remains only a few pedigrees. The exact prevalence, penetrance by age, annual threshold deterioration, speech-recognition trajectory, environmental modifiers, CI outcomes, and patient-reported outcomes are unknown. Modern ClinVar/gnomAD normalization, prospective international natural-history cohorts, and variant-specific longitudinal audiometry are priorities.

The 2024 mouse studies materially advance understanding: cell-specific RNA-seq identifies a failure to suppress supporting-cell programs; humanized alleles demonstrate that different single-nucleotide changes produce distinct synaptic and stereociliary pathologies; transcriptome-guided pharmacology provides temporary proof of principle; and adult in vivo editing establishes mutation-directed rescue after symptom onset. Nevertheless, genome editing remains experimental and should not be offered outside an appropriately authorized clinical trial. (zhu2024targetedgenomeediting pages 1-3, lewis2024pathologicalmechanismsand pages 17-18, lewis2024pathologicalmechanismsand pages 13-16, gwilliam2024acelltype–specific pages 1-2)

Selected primary and recent sources

Mencía et al. Nature Genetics. May 2009. “Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss.” PMID 19363479; DOI 10.1038/ng.355. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 50-MIR96, lenz2011hereditaryhearingloss pages 5-6)
Lewis et al. Nature Genetics. May 2009. PMID 19363478; DOI 10.1038/ng.369. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 50-MIR96, lewis2009anenuinducedmutation pages 1-2)
Soldà et al. Human Molecular Genetics. Advance publication October 28, 2011; volume publication 2012. DOI 10.1093/hmg/ddr493. Exact abstract conclusion: “a quantitative defect of this miRNA may contribute to NSHL.” (solda2012anovelmutation pages 1-2)
Aldè et al. Biomedicines. June 2023. DOI 10.3390/biomedicines11061616. (alde2023autosomaldominantnonsyndromic pages 16-17)
Gwilliam et al. Frontiers in Audiology and Otology. May 9, 2024. DOI 10.3389/fauot.2024.1400576. (gwilliam2024acelltype–specific pages 1-2)
Zhu et al. Science Translational Medicine. July 2024. DOI 10.1126/scitranslmed.adn0689. (zhu2024targetedgenomeediting pages 1-3)
Lewis et al. Genome Medicine. October 2024; 16:121. DOI 10.1186/s13073-024-01394-5. (lewis2024pathologicalmechanismsand pages 17-18, lewis2024pathologicalmechanismsand pages 13-16)

Knowledge-base caution: ontology identifiers, present-day ClinVar assertions, and population frequencies should be programmatically refreshed before ingestion. Historical MIR96 variant notation is not consistently compliant with current genomic HGVS, and the supplied MONDO identifier could not be independently confirmed from the retrieved evidence.

References

(OpenTargets Search: autosomal dominant nonsyndromic hearing loss 50-MIR96): Open Targets Query (autosomal dominant nonsyndromic hearing loss 50-MIR96, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(zhu2024targetedgenomeediting pages 1-3): Wenliang Zhu, Wan Du, Arun Prabhu Rameshbabu, Ariel Miura Armstrong, Stewart Silver, Yehree Kim, Wei Wei, Yilai Shu, Xuezhong Liu, Morag A. Lewis, Karen P. Steel, and Zheng-Yi Chen. Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microrna mutation. Science translational medicine, 16:eadn0689-eadn0689, Jul 2024. URL: https://doi.org/10.1126/scitranslmed.adn0689, doi:10.1126/scitranslmed.adn0689. This article has 32 citations and is from a highest quality peer-reviewed journal.
(lewis2024pathologicalmechanismsand pages 17-18): Morag A. Lewis, Maria Lachgar-Ruiz, Francesca Di Domenico, Graham Duddy, Jing Chen, Sergio Fernandez, Matias Morin, Gareth Williams, Miguel Angel Moreno Pelayo, and Karen P. Steel. Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human mir96 mutations. Oct 2024. URL: https://doi.org/10.1186/s13073-024-01394-5, doi:10.1186/s13073-024-01394-5. This article has 4 citations and is from a highest quality peer-reviewed journal.
(lewis2024pathologicalmechanismsand pages 13-16): Morag A. Lewis, Maria Lachgar-Ruiz, Francesca Di Domenico, Graham Duddy, Jing Chen, Sergio Fernandez, Matias Morin, Gareth Williams, Miguel Angel Moreno Pelayo, and Karen P. Steel. Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human mir96 mutations. Oct 2024. URL: https://doi.org/10.1186/s13073-024-01394-5, doi:10.1186/s13073-024-01394-5. This article has 4 citations and is from a highest quality peer-reviewed journal.
(gwilliam2024acelltype–specific pages 1-2): Kathleen Gwilliam, Michal Sperber, Katherine Perry, Kevin P. Rose, Laura Ginsberg, Nikhil Paladugu, Yang Song, Beatrice Milon, Ran Elkon, and Ronna Hertzano. A cell type–specific approach to elucidate the role of mir-96 in inner ear hair cells. Frontiers in audiology and otology, May 2024. URL: https://doi.org/10.3389/fauot.2024.1400576, doi:10.3389/fauot.2024.1400576. This article has 2 citations.
(friedman2009micrornasandepigenetic pages 8-9): Lilach M. Friedman and Karen B. Avraham. Micrornas and epigenetic regulation in the mammalian inner ear: implications for deafness. Mammalian Genome, 20:581-603, Oct 2009. URL: https://doi.org/10.1007/s00335-009-9230-5, doi:10.1007/s00335-009-9230-5. This article has 68 citations and is from a peer-reviewed journal.
(lenz2011hereditaryhearingloss pages 5-6): Danielle R. Lenz and Karen B. Avraham. Hereditary hearing loss: from human mutation to mechanism. Hearing Research, 281:3-10, Nov 2011. URL: https://doi.org/10.1016/j.heares.2011.05.021, doi:10.1016/j.heares.2011.05.021. This article has 73 citations and is from a domain leading peer-reviewed journal.
(solda2012anovelmutation pages 5-7): Giulia Soldà, Michela Robusto, Paola Primignani, Pierangela Castorina, Elena Benzoni, Antonio Cesarani, Umberto Ambrosetti, Rosanna Asselta, and Stefano Duga. A novel mutation within the mir96 gene causes non-syndromic inherited hearing loss in an italian family by altering pre-mirna processing. Human Molecular Genetics, 21(3):577-585, Oct 2012. URL: https://doi.org/10.1093/hmg/ddr493, doi:10.1093/hmg/ddr493. This article has 136 citations and is from a domain leading peer-reviewed journal.
(robusto2014inheritedhearingloss pages 91-92): MICHELA ROBUSTO. Inherited hearing loss: from gene variants to mechanisms of disease. ArXiv, Jan 2014. URL: https://doi.org/10.13130/m-robusto_phd2014-01-24, doi:10.13130/m-robusto_phd2014-01-24. This article has 1 citations.
(solda2012anovelmutation pages 1-2): Giulia Soldà, Michela Robusto, Paola Primignani, Pierangela Castorina, Elena Benzoni, Antonio Cesarani, Umberto Ambrosetti, Rosanna Asselta, and Stefano Duga. A novel mutation within the mir96 gene causes non-syndromic inherited hearing loss in an italian family by altering pre-mirna processing. Human Molecular Genetics, 21(3):577-585, Oct 2012. URL: https://doi.org/10.1093/hmg/ddr493, doi:10.1093/hmg/ddr493. This article has 136 citations and is from a domain leading peer-reviewed journal.
(solda2012anovelmutation pages 2-4): Giulia Soldà, Michela Robusto, Paola Primignani, Pierangela Castorina, Elena Benzoni, Antonio Cesarani, Umberto Ambrosetti, Rosanna Asselta, and Stefano Duga. A novel mutation within the mir96 gene causes non-syndromic inherited hearing loss in an italian family by altering pre-mirna processing. Human Molecular Genetics, 21(3):577-585, Oct 2012. URL: https://doi.org/10.1093/hmg/ddr493, doi:10.1093/hmg/ddr493. This article has 136 citations and is from a domain leading peer-reviewed journal.
(lewis2009anenuinducedmutation pages 1-2): Morag A Lewis, Elizabeth Quint, Anne M Glazier, Helmut Fuchs, Martin Hrabé De Angelis, Cordelia Langford, Stijn van Dongen, Cei Abreu-Goodger, Matias Piipari, Nick Redshaw, Tamas Dalmay, Miguel Angel Moreno-Pelayo, Anton J Enright, and Karen P Steel. An enu-induced mutation of mir-96 associated with progressive hearing loss in mice. Apr 2009. URL: https://doi.org/10.1038/ng.369, doi:10.1038/ng.369. This article has 402 citations and is from a highest quality peer-reviewed journal.
(lewis2024pathologicalmechanismsand pages 16-17): Morag A. Lewis, Maria Lachgar-Ruiz, Francesca Di Domenico, Graham Duddy, Jing Chen, Sergio Fernandez, Matias Morin, Gareth Williams, Miguel Angel Moreno Pelayo, and Karen P. Steel. Pathological mechanisms and candidate therapeutic approaches in the hearing loss of mice carrying human mir96 mutations. Oct 2024. URL: https://doi.org/10.1186/s13073-024-01394-5, doi:10.1186/s13073-024-01394-5. This article has 4 citations and is from a highest quality peer-reviewed journal.
(zhu2024targetedgenomeediting pages 12-14): Wenliang Zhu, Wan Du, Arun Prabhu Rameshbabu, Ariel Miura Armstrong, Stewart Silver, Yehree Kim, Wei Wei, Yilai Shu, Xuezhong Liu, Morag A. Lewis, Karen P. Steel, and Zheng-Yi Chen. Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microrna mutation. Science translational medicine, 16:eadn0689-eadn0689, Jul 2024. URL: https://doi.org/10.1126/scitranslmed.adn0689, doi:10.1126/scitranslmed.adn0689. This article has 32 citations and is from a highest quality peer-reviewed journal.
(goel2024micrornaandrare pages 4-6): Himanshu Goel and Amy Goel. Microrna and rare human diseases. Genes, 15:1243, Sep 2024. URL: https://doi.org/10.3390/genes15101243, doi:10.3390/genes15101243. This article has 20 citations.
(rosa2024hearinglossgenetic pages 4-5): Maria Agustina De Rosa, Maria T. Bernardi, Soledad Kleppe, and Katherina Walz. Hearing loss: genetic testing, current advances and the situation in latin america. Genes, 15:178, Jan 2024. URL: https://doi.org/10.3390/genes15020178, doi:10.3390/genes15020178. This article has 14 citations.
(tropitzsch2023variabilityincochlear pages 1-5): Anke Tropitzsch, Thore Schade-Mann, Philipp Gamerdinger, Saskia Dofek, Björn Schulte, Martin Schulze, Sarah Fehr, Saskia Biskup, Tobias B. Haack, Petra Stöbe, Andreas Heyd, Jennifer Harre, Anke Lesinski-Schiedat, Andreas Büchner, Thomas Lenarz, Athanasia Warnecke, Marcus Müller, Barbara Vona, Ernst Dahlhoff, Hubert Löwenheim, and Martin Holderried. Variability in cochlear implantation outcomes in a large german cohort with a genetic etiology of hearing loss. Ear and Hearing, 44:1464-1484, Jul 2023. URL: https://doi.org/10.1097/aud.0000000000001386, doi:10.1097/aud.0000000000001386. This article has 40 citations and is from a highest quality peer-reviewed journal.
(cuda2024improvingqualityof pages 1-2): D. Cuda, M. Manrique, Á. Ramos, M. Marx, R. Bovo, R. Khnifes, O. Hilly, J. Belmin, G. Stripeikyte, P. L. Graham, C. J. James, P. V. Greenham, and I. Mosnier. Improving quality of life in the elderly: hearing loss treatment with cochlear implants. BMC Geriatrics, Jan 2024. URL: https://doi.org/10.1186/s12877-023-04642-2, doi:10.1186/s12877-023-04642-2. This article has 49 citations and is from a domain leading peer-reviewed journal.
(zeitler2024americancochlearimplant pages 1-3): Daniel M. Zeitler, Sandra M. Prentiss, Sarah A. Sydlowski, and Camille C. Dunn. American cochlear implant alliance task force: recommendations for determining cochlear implant candidacy in adults. The Laryngoscope, Jul 2024. URL: https://doi.org/10.1002/lary.30879, doi:10.1002/lary.30879. This article has 55 citations.
(zhu2024targetedgenomeediting pages 14-16): Wenliang Zhu, Wan Du, Arun Prabhu Rameshbabu, Ariel Miura Armstrong, Stewart Silver, Yehree Kim, Wei Wei, Yilai Shu, Xuezhong Liu, Morag A. Lewis, Karen P. Steel, and Zheng-Yi Chen. Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microrna mutation. Science translational medicine, 16:eadn0689-eadn0689, Jul 2024. URL: https://doi.org/10.1126/scitranslmed.adn0689, doi:10.1126/scitranslmed.adn0689. This article has 32 citations and is from a highest quality peer-reviewed journal.
(alde2023autosomaldominantnonsyndromic pages 16-17): Mirko Aldè, Giovanna Cantarella, Diego Zanetti, Lorenzo Pignataro, Ignazio La Mantia, Luigi Maiolino, Salvatore Ferlito, Paola Di Mauro, Salvatore Cocuzza, Jérôme René Lechien, Giannicola Iannella, Francois Simon, and Antonino Maniaci. Autosomal dominant non-syndromic hearing loss (dfna): a comprehensive narrative review. Biomedicines, 11:1616, Jun 2023. URL: https://doi.org/10.3390/biomedicines11061616, doi:10.3390/biomedicines11061616. This article has 65 citations.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	15
Resolved	15
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	15
On topic	8
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	27
Resolved	26
Unresolved (possible confabulation)	1
Obsolete	0
Unverifiable	0
Terms whose name was checked	1
Terms named correctly	0
Terms named as a different term	1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

MONDO:0013114 (2 mentions) - the report calls it "if available"; MONDO calls it autosomal dominant nonsyndromic hearing loss 50

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

HP:0000404 (1 mention) - HP does not contain this term

Ask OpenScientist

OpenScientist Report

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

External Assertions

Medical Actions

Diagnosis

Progression

Prevalence

Related Datasets

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

DFNA50 due to MIR96 mutation: disease-characteristics research report

Executive summary

1. Disease information

Definition and nomenclature

Identifiers

Evidence granularity

2. Etiology, risk, protection, and gene–environment interaction

Primary cause

Genetic risk factors

Environmental and lifestyle factors

Protective factors

3. Phenotypes

Core phenotype

Severity, progression, and frequency estimates

Behavioral, laboratory, and quality-of-life findings

4. Genetic and molecular information

Gene annotation

Established pathogenic variants

Functional consequence and disease mechanism class

5. Environmental information

6. Mechanism and pathophysiology

Ordered causal chain

Molecular pathways and cellular processes

Tissue damage, metabolism, and immunity

Molecular profiling and advanced technologies

7. Anatomical structures affected

Organ and tissue levels

Cell level

Subcellular level and localization

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical evaluation

Molecular testing

Diagnostic criteria and differential diagnosis

Screening

11. Outcome and prognosis

12. Treatment and current implementation

Current clinical care

Experimental pharmacotherapy